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ABSTRACT 
PODOCYTE DEDIFFERENTIATION AND GLOMERULAR INJURY MEDIATED BY 
LYSOSOME DYSFUNCTION: ROLE OF ACID CERAMIDASE 
 
By Guangbi Li 
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Doctor of Philosophy at the Virginia Commonwealth University 
 
Virginia Commonwealth University, 2017 
 
Advisor: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology 
 
Cell differentiation and senescence in podocytes are attributed to normal autophagy and 
associated cellular activities. It is possible that derangement of autophagy under different 
pathological conditions activates or enhances podocyte dedifferentiation leading to glomerular 
injury and ultimate glomerular disease. To test this hypothesis, we first tested whether 
autophagic deficiency due to lysosome dysfunction enhances podocyte dedifferentiation and 
explored the molecular mechanisms by which this lysosome dysfunction trigger or enhance 
podocyte dedifferentiation. By Western blot and confocal analysis, lysosome inhibition using an 
inhibitor or siRNA of V-ATPase inhibitor was found to markedly decrease the epithelial markers 
(P-cadherin and ZO-1) and increase the mesenchymal markers (FSP-1 and α-SMA). This 
enhancement of podocyte dedifferentiation (formerly referred to as epithelial-mesenchymal 
transition, EMT) was accompanied by deficient autophagic flux, as demonstrated by marked 
increases in LC3B-II and p62/Sequestosome 1. However, inhibition of autophagosome formation 
using spautin-1 (SP-1) significantly attenuated both enhancement of podocyte dedifferentiation 
and deficiency of autophagic flux. To explore the mechanisms by which deficient autophagic 
flux enhances podocyte dedifferentiation, we tested the role of accumulated p62 as a signal hub 
in this process. Neither the nuclear factor erythroid 2-related factor 2 (Nrf2) nor nuclear factor 
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kappa (NFκ)-light-chain-enhancer pathway regulating p62 function was found to contribute to 
enhanced dedifferentiation. However, inhibition of cyclin-dependent kinase 1 (CDK1) activity 
reduced the phosphorylation of p62 and enhanced podocyte dedifferentiation similar to lysosome 
dysfunction, which indicates that enhanced podocyte dedifferentiation due to lysosome 
dysfunction may be triggered by accumulation of p62 and associated reduction of p62 
phosphorylation. Given the essential role of sphingolipid-ceramide metabolism and transient 
receptor potential-mucolipin-1 (TRPML1) channel activity in lysosome function, we next sought 
to test whether altered ceramide metabolism by acid ceramidase (AC) leads to deficient 
lysosome trafficking and fusion to autophagosome in podocytes and thereby results in 
autophagic deficiency and podocyte dedifferentiation. Inhibition of AC by a potent and selective 
inhibitor, carmofur markedly reduced lysosome trafficking and fusion to both autophagosomes 
and multivesicular bodies (MVBs). Concurrently, enhancement of podocyte AC activity or 
exposure of podocytes to sphingosine, a product of ceramide metabolism by AC, remarkably 
increased lysosome trafficking and fusion to autophagosomes and MVBs, indicating that AC 
activity is critical for lysosome function in podocytes. To further explore the mechanisms by 
which AC activity contributes to lysosome trafficking, we examined the effects of various 
sphingolipids related to ceramide metabolism on transient receptor potential-mucolipin-1 
(TRPML1) channel, a Ca2+ channel essential for lysosome trafficking and function. It was found 
that sphingomyelin (SM), a precursor for ceramide production blocked TRPML1 channel 
activity induced by ML-SA1 (a specific TRPML1 agonist), while ceramide had no effects on 
TRPML1 channel activity induced by ML-SA1. Interestingly, sphingosine, an AC product of 
ceramide remarkably enhanced TRPML1 channel activity induced by ML-SA1. These results 
demonstrate that AC product of ceramide, sphingosine may enhance TRPML1 channel activity, 
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but an upstream sphingolipid, SM may exert inhibitory action on lysosome TRPML1 channel 
activity. AC may be a key enzyme gating TRPML1 channels by production of sphingosine and 
changes in upstream substrate SM. These results from in vitro cell studies led us hypothesize that 
a deficient AC activity may induce podocyte injury through lysosome dysfunction, leading to 
glomerular damage and proteinuria. To test this hypothesis, we generated a mouse colony with 
podocyte-specific gene deletion of AC α subunit, namely, Asah1fl/fl/PodoCre mice. In these mice, 
severe proteinuria and albuminuria were shown compared to their littermates, but they were 
without global and even focal glomerular sclerosis. These mice also had hypoalbuminemia and 
edema, and under transmission electron microscopy (TEM) ultrastructural changes of podocytes 
from their glomeruli exhibited diffuse and flat foot process (podocyte effacement), vacuolation, 
and microvillus formation, which were not observed in their littermates. Treatment of 
corticosteroids and specific expression patterns of dystroglycans in glomeruli confirmed that 
albuminuria in these Asah1fl/fl/PodoCre mice may be resistant to corticosteroids. Together, these 
results from in vivo animal studies indicate that podocyte-specific gene deletion of AC α subunit 
may induce a corticosteroid-resistant minimal change disease (MCD). Based on all results from 
our in vitro and in vivo studies, we conclude that the normal lysosome function is essential for 
maintenance of autophagic flux and podocyte differentiation, which is regulated by a lysosomal 
AC-mediated signaling pathway through a TRPML1 channel gating mechanism. AC gene defect 
or deficiency of its activity induces podocyte injury, which is characterized by a corticosteroid-
resistant MCD. These findings indicate an important pathological role of AC deficiency and 
associated lysosome dysfunction in podocytes injury and corticosteroid-resistant MCD, which 
may help develop novel therapeutic strategies for prevention or treatment of corticosteroid-
resistant MCD. 
 1 
CHAPTER ONE 
INTRODUCTION 
1.1 Podocyte dedifferentiation and glomerular diseases 
Cell differentiation is the process by which a less specialized cell type becomes a more 
specialized cell type, which is a cell mature process in a variety of differentiable cells. As the 
representative of immature cells, embryonic stem cells (ESC) are pluripotent cells which give 
rise to all somatic cell types in the embryo. In adult organisms, the adult stem cells (ASCs) 
maintain the normal regeneration of many tissues such as blood, skin, intestinal tissues, and renal 
glomerular or tubular cells. Under different physiological and pathological conditions, ASCs 
may act as a repair system for human or animal organs, which can replace the loss or 
dysfunctional specialized cells. Recent studies have suggested that glomerular parietal epithelial 
cells (GPECs) may serve as progenitor cells for podocytes and thus they may have a potential 
role in glomerular repair by replacing, in part or completely, the loss of podocyte (1-5). There are 
evidences that podocytes can derive from GPECs in adolescent mice (1). In certain glomerular 
diseases, such as focal segmental glomerular sclerosis (FSGS), membrane nephropathy, and 
aging nephropathy, GPECs were found to express proteins previously considered specific for 
podocytes (6-8). It has been demonstrated that the therapeutic effect of prednisone, a first line 
therapeutic glucocorticoid for focal segmental glomerular sclerosis, is attributed to the 
enhancement of podocyte regeneration by GPECs as a progenitor cells (9). 
 
On the other hand, the reversal of cell differentiation process, namely, cell 
dedifferentiation, is normally considered as a danger factor under pathological conditions. It is 
broadly accepted that dedifferentiation is an aberration of the normal development of cell cycle 
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which results in tumorigenesis and promote fibrosis (10). Consistent with this theory, the 
transformation into stem cell-like status of podocyte, a highly specialized cell with a unique 
structure, has been demonstrated as one of the pathogeneses of glomerular disease (11). Since 
podocytes develop from mesenchymal cells via a mesenchymal-to-epithelial transition (MET), it 
is hypothesized that podocyte dedifferentiation is the reversal of this process (12). In many 
previous studies, epithelial-to-mesenchymal transition (EMT) or transdifferentiation was 
generally used for podocyte phenotype transition upon different pathological stimuli. However, it 
is recently realized that the traditional definition of a podocyte as an epithelial cell is too 
simplistic, because the podocyte has features of a partial mesenchymal and partial epithelial cell. 
Also, podocytes are developmentally derived from mesenchymal stem cells. It is now widely 
accepted that so called EMT in podocytes are mainly due to reversal of their mesenchymal 
features, namely, dedifferentiation. However, some researchers suggested that such pathological 
changes in podocytes can be named as podocyte disease transformation, but this new name of 
podocyte phenotype transition is not yet widely accepted (11). We are using podocyte 
dedifferentiation to more accurately represent the reversal of its mesenchymal features observed 
in our experiments. 
 
In 1980, an in vitro model system for studying the glomerular epithelium exposed on the 
surfaces of kidney slides was described (13). In these studies, an in vitro incubation of podocytes 
at 37°C induced transformation of these cells into a compact group of rounded but viable cells. 
At lower incubation temperatures, the differentiation process of podocytes was significantly 
inhibited. This finding was the first direct evidence proving podocyte transformation and 
potential dedifferentiation, which was followed by many further studies to characterize podocyte 
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dedifferentiation and to explore the underlying molecular mechanisms. Based on these studies, it 
has been indicated that the hallmarks of podocyte dedifferentiation includes but is not limited to 
the suppressed expression of P-cadherin, ZO-1, and nephrin with concomitant upregulation of α-
ASM, N-cadherin, SNAIL, SLUG, desmin, fibronectin, and collagen I (14, 15). During 
dedifferentiation, podocytes lose their highly arborized morphology and adopt a more 
cobblestone-like morphology. As a result, foot process effacement diminishes the ability of 
podocytes to restrict urinary protein leaking through glomerular filtration membrane, which may 
lead to proteinuria, albuminuria and ultimate nephrotic syndrome and other glomerular fibrotic 
diseases. Concurrently, podocytes with effaced foot processes have less contact with the 
glomerular basement membrane, making podocyte loss much more likely. Moreover, the 
increased synthesis of extracellular matrix components such as fibronectin and collagen I due to 
podocyte effacement may contribute to glomerular basement membrane thickening, leading to 
glomerulosclerosis. Proteinuria, in particular, albuminuria accelerates kidney disease progression 
to end-stage renal disease (ESRD) through induction of glomerular and tubular inflammasome 
activation, increases in chemokines or cytokine production and complement activation, which 
may lead to inflammatory cells infiltration in the interstitium and sustained fibrogenesis. 
 
Previous studies have demonstrated that podocyte dysfunction and glomerular sclerosis 
may be due to podocyte dedifferentiation in response to a variety of pathological stimuli and 
endogenously produced pathogenic factors such as HIV-1 Nef (16-19), transforming growth 
factor-β (20-22), matrix metalloproteinase-9 (23), Notch-1 (24), RSAD2 (25), integrin-linked 
kinase (26, 27), PKC-α/PKC-βI (28), NADPH oxidase (29),  connective tissue growth factor/β-
catenin (27, 30), PI3-K/ Akt-signaling pathway (31), Rac1/PAK1 signaling (32), high glucose 
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(30, 33-38), macrophage migration inhibitory factor (39), phosphorylation of caveolin-1 (40), 
NFATc3 (41), carboxymethyl lysine/ZEB2 (42), and glycogen synthase kinase 3β (38). It is 
expected that the progress in understanding of the molecular mechanisms mediating podocyte 
dedifferentiation under different pathological conditions would tremendously contribute to the 
development of potential novel therapeutic strategies for patients with various glomerular 
diseases. 
 
It has been reported that HIV-associated nephropathy (HIVAN) is a leading cause of ESRD 
in HIV-1 seropositive patients (43). In HIVAN patients, podocytes were found to exhibit a 
unique phenotype with loss of many differentiation markers, showing more proliferative, 
dedifferentiable, and dysfunctioning (44-46). These pathological changes of podocytes appear to 
be a direct result of HIV-1 protein expression, specifically Nef and Vpr (16, 18, 47, 48). Diabetic 
kidney disease (DKD) is the leading cause of ESRD worldwide, which is considered as a single 
strongest predictor of the mortality in patients with diabetes (49). Multiple researchers have 
reported increased expression of Wnt and excessive activation of canonical β-catenin signaling in 
diabetic glomeruli (50, 51), which are important cell dedifferentiating and proliferative markers. 
Transgenic mice with podocyte-specific, stabilized β-catenin expression developed basement 
membrane thickening and mild albuminuria, resembling early changes in human DKD (50). 
These results suggest that excessive Notch and Wnt activation in DKD diabetic nephropathy is 
maladaptive, which may contribute to podocyte dedifferentiation and disease progression. In 
previous studies, we have demonstrated that hHcys induces dedifferentiation of podocytes, 
which may represent a novel mechanism of hHcys-induced podocyte dysfunction and glomerular 
sclerosis. As the dominant source of O2
.- in many non-phagocytic cells, especially in the kidney 
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(52-56), activation of NADHP oxidase (Nox) has been shown to contribute to hHcys-enhanced 
podocyte dedifferentiation (29). Growth hormone (GH), a hormone regulating cell differentiation 
and growth, has also been demonstrated to reverse Hcys-induced podocyte dedifferentiation and 
to ameliorate hHcys-induced glomerular injury (57, 58). These results suggest a crucial role of 
podocyte dedifferentiation in the sclerogenic mechanism of hHcys during the progression of 
glomerular injury. However, it remains poorly understood how podocyte dedifferentiation is 
activated and regulated in response to different pathological stimuli. 
 
1.2 Autophagic deficiency and podocyte dedifferentiation 
The term autophagy was first used in 1963 by Christian de Duve, the 1974 Nobel Prize 
Laureate for his work on lysosomes. It described the phenomenon associated with single- or 
double-membraned vesicles that contained cytoplasm, including organelles, at various stages of 
digestion. Since then, at least three forms of autophagy have been reported including chaperone-
mediated autophagy, microautophagy, and macroautophagy, which were based on their 
physiological functions and the mode of cargo delivery to lysosomes. However, many studies 
have focused on the original concept of de Duve, which likely described macroautophagy. It is a 
major regulated catabolic mechanism that eukaryotic cells use to degrade long-lived proteins and 
organelles (59, 60). Therefore, unless there is special definition or description in a study about 
other two types of autophagy, macroautophagy is often referred to as autophagy in literature. 
 
Autophagy is a basic mechanism of degrading unnecessary or dysfunctional cell 
components. It is characterized by the engulfment of the targeted components in double-
membrane bound autophagosomes followed by their fusion with lysosomes. The contents of 
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autophagolysosomes are then degraded by lysosomal hydrolases to produce various enzymatic 
catabolites including amino acids, free fatty acids and others, which are rapidly made available in 
the cytoplasm for recycling (61). In somatic cells, normal autophagic flux controls the quality of 
long-lived proteins and organelles. Since misfolded proteins and functionally impaired 
organelles are targeted and degraded by autophagic flux, their accumulation with toxic effects 
are prevented (62). 
 
Until the early 1990s, the knowledge of autophagy was limited to understanding of its 
morphological and biochemical characteristics, but its molecular mechanisms or regulatory 
pathways were poorly understood. Over the last decade, due to the discovery of yeast autophagy 
genes (Atg genes) followed by the identification of their mammalian homologues (63-66) 
numerous studies have been done to elucidate the molecular machinery of this main cellular 
homeostatic process and its regulatory mechanisms. Also, significant advances have been made 
to reveal its roles under physiological and pathological conditions (60, 67-77). 
 
While the functions of autophagic flux in somatic cells are well characterized, the role of 
autophagy in stem cells and dedifferentiated cells is much less understood. In recent studies, 
autophagy was shown to be involved in the homeostatic control and maintenance of the self-
renewal capacity of stem cells. In particular, autophagic flux was demonstrated to participate in 
stem cell differentiation and somatic reprogramming (78). In this regard, upregulation of 
autophagy is critically implicated in differentiation of neural stem cells and cardiac stem cells 
(79-81). Autophagy has also been reported to be rapidly upregulated during early differentiation 
of mouse embryonic stem cells and human embryonic stem cells, and impaired autophagic flux 
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led to early embryonic lethality, further confirming a critical role of autophagy in stem cell 
differentiation (82-86). In podocytes, previous studies have revealed that LC3-I is processed to 
LC3-II during the podocyte differentiation and recovery from puromycin aminonucleoside-
induced nephrosis, which indicates that autophagy plays an important role in podocyte 
differentiation (87). Recently, our observations revealed that normal expression of CD38, a 
multifunctional protein involving in a number of signaling pathways, importantly contributes to 
the differentiation and function of podocytes and the defect of this gene expression may be a 
critical mechanism inducing podocyte dedifferentiation and consequently resulting in glomerular 
injury and sclerosis (88). Also, we have found that CD38 controls lysosome function and thus 
contributes to autophagy maturation in podocytes, which further confirms the vital role of 
autophagy in maintenance of podocyte differentiation (89). Therefore, autophagic deficiency 
may be an important mechanism mediating podocyte dedifferentiation under pathological 
conditions. 
 
1.3 Ceramide metabolism and lysosome-dependent autophagic flux 
As a sphingolipid involved in many signaling pathways, ceramide has been reported to 
inhibit autophagic flux (90, 91). Ceramide production is mainly mediated via the hydrolysis of 
membrane sphingomyelin by various sphingomyelinases such as acid sphingomyelinase (ASM) 
or by de novo synthesis via serine palmitoyltransferase and ceramide synthase (92). 
Subsequently, ceramide is metabolized into sphingosine by various ceramidases such as acid 
ceramidase (AC), and sphingosine can be further converted to sphingosine-1-phosphate (S1P) 
via sphingosine kinase (92). In our recent studies, enhanced activity of ASM and associated 
increase in ceramide production were shown to play a pivotal role in mediating podocyte injury 
 8 
and glomerulosclerosis during hHcys and obesity (93-95). However, it remains unknown 
whether altered ceramide metabolism leads to autophagic deficiency and consequent podocyte 
dedifferentiation under different pathological conditions. 
 
There is considerable evidence that lysosomes have trafficking function within different 
cells (96-102). Recent studies in our lab also showed that lysosome trafficking is a main 
regulatory mechanism of autophagic flux, which may depend upon the Ca2+ bursts from 
lysosomes. It has been indicated that although small amounts of Ca2+ released from a single 
lysosome may not be enough to activate global Ca2+ release from the sarcoplasmic reticulum 
(SR), they may be enough to drive the lysosome moving along microtubules to meet with other 
cellular vesicles such as autophagosomes, endosomes, MVBs, and SR (103-108). This Ca2+-
dependent lysosome trafficking was also observed in various types of cells (109-113).  In 
addition to lysosome trafficking, its fusion to cell plasma membrane, endosomes, MVBs, 
phagosomes, autophagosomes or other organelles is also a Ca2+-dependent event (107, 114-116). 
It is well known that Ca2+ enters lysosomal compartment by H+/Ca2+ exchange under resting 
condition and is released through transient receptor potential-mucolipin-1 (TRPML1) channels in 
response to endogenously produced nicotinic acid adenine dinucleotide phosphate (NAADP) 
(103, 107, 108, 117, 118) or other factors like PIPs (PI(3,5)P2) and irons (109, 111, 119). More 
channels such as two-pore channels may also be implicated in lysosomal Ca2+ release, but they 
may form hybrids with TRPML1 and need accessory proteins to exert their effect (97, 120). 
More recently, lysosomal TRPML1 channel activity regulated by sphingolipids has been shown 
to be a key mechanism determining lysosome trafficking. Accumulated sphingomyelin inhibited 
its activity and reduced lysosomal Ca2+ release, leading to failure of lysosome trafficking and 
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lysosomal storage disease as shown in Niemann-Pick disease (112, 121). Sphingosine, a 
ceramide metabolite via AC activated TRPML1 channels promoting lysosome Ca2+ release and 
trafficking in some epithelial cells. These results support a scientific premise that lysosome Ca2+ 
bursts through TRPML1 channels may be fine controlled by sphingolipids. Based on these 
results, we hypothesize that AC-mediated sphingolipid signaling may gate TRPML1 channels in 
podocytes to control Ca2+-dependent lysosome trafficking to autophagosome that governs 
autophagic flux. Altered ceramide metabolism due to AC dysfunction inhibits TRPML1 channel 
activity and lysosome trafficking to autophagosome, leading to autophagic deficiency and 
consequent podocyte dedifferentiation or dysfunction. 
 
1.4 Aims of the study 
The hypothesis to be tested in the present study states that: autophagic deficiency due to 
lysosome dysfunction contributes to podocyte dedifferentiation leading to glomerular injury and 
lysosome trafficking to lysosomes is fine controlled by lysosomal AC-mediated signaling 
pathway that gates TRPML1 channel. 
 
The specific aims are: 
1. To determine whether lysosome-mediated autophagic flux serves as a fine control 
mechanism for differentiation of mouse podocytes and to define the signaling pathways 
linking autophagy to podocyte differentiation. 
2. To determine whether altered ceramide metabolism via AC induces lysosome 
dysfunction with a focus on deranged lysosome trafficking associated with reduced 
TRPML1 channel activity. 
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3. To determine whether derangement of lysosome trafficking results in podocyte 
dedifferentiation or dysfunction in mice with podocyte-specific AC gene deletion. 
 
The overall hypothesis and the specific aims of this project are schematically represented in 
Figure 1. 
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Figure 1. The working hypothesis. Autophagic flux determined by normal lysosome 
function is crucial for the control of differentiation status in podocytes. If lysosome function is 
disrupted, podocytes will undergo dedifferentiation. Such lysosome dysfunction may be 
associated with deficient lysosome trafficking and fusion with autophagosomes (APs), two 
major processes in autophagic flux. In response to pathological stimuli, lysosome trafficking 
or fusion to APs is attenuated through abnormal ceramide metabolism and transient receptor 
potential-mucolipin 1 (TRPML1) channel activity, which may be attributed to acid 
ceramidase (AC) deficiency and reduced production of sphingosine or sphigosine-1-
phosphate (S1P). The dedifferentiated podocytes lose their epithelial properties and gain more 
mesenchymal features, which increases their migration capability, detachment and 
interactions with extracellular matrix, leading to glomerular injury and proteinuria. 
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CHAPTER TWO 
GENERAL METHODS 
 
2.1 Cell culture 
A conditionally immortalized mouse podocyte cell line, graciously provided by Dr. Paul E. 
Klotman (Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, 
New York, USA), was constructed with a temperature-sensitive variant of the simian virus 
(SV40) containing a large T antigen (tsA58) inducible by interferon-γ at 33°C, allowing for 
cellular proliferation. These cells were cultured and maintained on collagen-coated flasks in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 U/ml recombinant mouse 
interferon-γ, 100 U/ml penicillin and 100 mg/ml streptomycin.  The podocytes were then 
passaged and allowed to differentiate to a mature cell type at 37°C for two weeks without 
interferon-γ before use in experiments. 
 
Podocytes were treated with Baf A1 (Baf), a potent vacuolar-type H+-ATPase inhibitor, at a 
concentration of 10 nM for 24 hours. Rapamycin (100 nM), 7-keto (5 μg/mL), Spautin-1 (2 µM), 
Bortezomib (1 nM), and RO-3306 (200 nM) were added to the cells 1 hour prior to Baf 
treatment. As a selective acid ceramidase inhibitor, Carmofur was used to treat podocytes at a 
concentration of 10 nM for 24 hours. 
 
2.2 Lipid-mediated transfection 
The scrambled RNA, vacuolar H+-ATPase siRNA, Nrf2 siRNA, and NF-κB siRNA were 
purchased from Qiagen, Valencia, CA, USA. The scrambled RNA was confirmed as non-
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silencing double-strand RNA and used as the control in the present study. Podocytes were serum 
starved for 12 h and then transfected with small interfering RNA (siRNA) or scrambled RNA 
using siLentFect Lipid Reagent (Bio-Rad, Hercules, CA, USA). After 24 h of incubation at 
37°C, the medium was changed, and Baf (10 nM) was added into the medium for indicated time 
span in different protocols. 
 
2.3 Nucleofection 
Podocytes were transfected with GCaMP3-ML1 plasmid directly to the nucleus via 
nucleofector technology developed by Lonza (Basel, Switzerland). This technology involves the 
temporary creation of small pores in the membrane through electrical impulses together with 
cell-specific solutions to deliver substrates through the cytoplasm and into the nuclear 
membrane. Podocytes were trypsinized, counted, and 1 x 106 cells were gently centrifuged at 
90xg for 10 min at RT. Cells were resuspended in SF Cell Line nucleofector solution containing 
2 μg plasmid DNA and then transferred into a certified cuvette. The cuvette was placed into the 
nucleofector system and subject to cell-type specific program DS-150, chosen based on 
optimization experiments. Nucleofected cells were resuspended with pre-warmed medium and 
transferred to cultured plates for use in experiments. 
 
2.4 Western blot analysis 
Western blot analysis was performed as described previously (57). In brief, homogenates 
from cultured podocytes were prepared using sucrose buffer containing protease inhibitors. After 
boiling for 5 min at 95°C in a 5× loading buffer, 20 µg of total proteins were subjected to SDS-
PAGE, transferred onto a PVDF membrane and blocked by solution with dry milk. Then, the 
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membrane was probed with primary antibodies of anti-ZO-1 (1:1000, Invitrogen), anti-P-
cadherin (1: 1000, R&D System), anti-α-SMA (1:5000, R&D System), anti-FSP-1 (1:1000, 
Abcam), anti-LC3B (1:1000, Cell Signaling Technology), anti-LAMP1 (1:1000, Novus 
Biologicals), mouse anti-p62 (1:5000, Abcam, Cambridge, MA, USA), rabbit anti-phospho-p62 
(1:1000, Cell Signaling Technology, Beverly, MA, USA) or anti-β-actin (1:5000, Santa Cruz 
Biotechnology) overnight at 4 °C followed by incubation with horseradish peroxidase-labeled 
IgG (1:5000). The immunoreactive bands were detected by chemiluminescence methods and 
visualized on Kodak Omat X-ray films. Densitometric analysis of the images obtained from X-
ray films was performed using the Image J software (NIH, Bethesda, MD, USA). 
 
2.5 Immunofluorescence microscopy 
Double-immunofluorescence staining was performed using cultured podocytes on cover 
slips. After fixation, the cells were incubated with rabbit anti-podocin (1: 200 dilution, Sigma, St. 
Louis, MO, USA). At the same time, goat anti-FSP-1 (1:50 dilution), goat anti-ZO-1 (1:50 
dilution, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), goat anti-P-cadherin (1:25 
dilution), or mouse anti-α-SMA (1:300 dilution, R&D system, Minneapolis, MN, USA) was 
added to the cell slides and then incubated overnight at 4°C. For examination of lysosome 
trafficking and fusion to MVBs, the cells were incubated with rat anti-Lamp-1 (1:200 dilution, 
Novus Biologicals, Littleton, CO, USA). At the same time, mouse anti-VPS16 (1:100 dilution, 
Abcam, Cambridge, United Kingdom) or mouse anti-Annexin-II (1:100 dilution, Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) was added to the cell slides and then incubated 
overnight at 4°C. After washing, the slides were incubated with corresponding Alex-488-labeled 
secondary antibody and Alex-555-labeled secondary antibodies and then mounted and subjected 
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to examinations using a confocal laser scanning microscope (Fluoview FV1000, Olympus, 
Japan). Frozen mouse kidneys were also fixed in acetone, blocked, and then incubated with the 
same aforementioned primary antibodies overnight at 4°C. For confirmation of podocyte-specific 
EGFP expression, frozen kidney sections were only incubated with rabbit anti-podocin 1: 200 
(Sigma, St. Louis, MO, USA). After washing, the slides were incubated with corresponding the 
Alex-555-labeled secondary antibodies and then mounted and subjected to examinations using a 
confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan). Image Pro Plus 
software (version 6.0; Media Cybernetics, Bethesda, MD) was used to analyze colocalization, 
which was expressed as the Pearson correlation coefficient. 
 
2.6 GCaMP3 Ca2+ imaging 
At 18–24 h after nucleofection with GCaMP3-ML1, podocytes were used for experiments. 
The fluorescence intensity at 470 nm (F470) was monitored using the EasyRatioPro system. 
Lysosomal Ca2+ release was measured under a ‘low’ external Ca2+ solution, which contained 145 
mM NaCl, 5 mM KCl, 3 mM MgCl2, 10 mM glucose, 1 mM EGTA and 20 mM HEPES (pH 
7.4). Ca2+ concentration in the nominally free Ca2+ solution is estimated to be 1–10 μM. With 1 
mM EGTA, the free Ca2+ concentration is estimated to be < 10 nM based on the Maxchelator 
software (http://maxchelator.stanford.edu/). 
 
2.7 Whole-cell patch clamp recording 
Whole-cell planar patch-clamp recordings were performed in cultured murine podocytes. 
The planar patch-clamp technology combined with a pressure control system (Port-a-Patch, 
Nanion Technologies) was applied as previously described (122). Ion currents were recorded, 
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filtered, and analyzed using an Axopatch 200B amplifier, an Axon Digidata 1550B low-noise 
data acquisition system, and the pClamp10 software (Axon instruments). Seal resistance was 
higher than 1 GΩ. Internal solution contained 50 mM CsCl, 10 mM NaCl, 60 mM Cs fluoride, 
20 mM EGTA, and 10 mM Hepes/CsOH. External solution contained 140 mM NaCl, 4 mM 
KCl, 1 mM MgCl2, 2 mM CaCl2, 5 mM D-Glucose monohydrate, and 10 mM Hepes/NaOH. 
Seal enhancer contained 80 mM NaCl, 3 mM KCl, 10 mM MgCl2, 35 mM CaCl2, and 10 mM 
Hepes/HCl. Podocytes were stimulated by bath application of compounds. 
 
2.8 Isolation of lysosomes from podocytes 
After treatment with Vacuolin-1 (1 µM) for 2 hours, isolation of lysosomes was performed. 
After washing podocytes with pre-cooled PBS, pre-cooled homogenization buffer was used for 
detachment of podocytes by a cell scraper. Cell suspension in glass-grinding vessel was 
homogenized using a Teflon pestle operated at 900 rotations per minute (rpm). The homogenate 
was then transferred to a 1.5 ml microfuge test tube and centrifuge at 14,000g for 15 min at 4°C. 
After centrifuge, the middle part of supernatant was transferred to a 10-ml polycarbonate 
centrifuge tube. An equal volume of 16 mM CaCl2 was added to precipitate lysosomes. After 
being shaken on a rotary shaker at 100 rpm for 5 min at 4°C, supernatant was centrifuged at 
25,000g for 15 min at 4°C in an ultracentrifuge. The supernatant was discarded and the pellet 
was resuspended in one volume of ice cold washing buffer. The suspension was centrifuged at 
25,000 g for 15 min at 4°C in an ultracentrifuge. After supernatant being discarded, the pellet 
containing lysosomes was resuspended in 40 μl of washing buffer, which was used for whole-
lysosome patch clamp recording. All steps were performed on ice to minimize the activation of 
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damaging from intracellular phospholipases and proteases. Lysosomes was used for 
electrophysiological recordings within 3 hours of isolation to keep lysosomes fresh. 
 
Homogenization Buffer 
Sucrose                 0.25 M 
Tris                       10 mM 
Adjust pH to 7.4 with HCl, sterilize by passing through a 0.2 μm filter, prepare 1 ml aliquots, 
and store at - 20°C for several months. Before use, add 40 μl of Complete Protease Inhibitor 
Cocktail (final concentration 1×) per aliquot of homogenization buffer. 
 
Washing Buffer 
KCl                        150 mM 
Tris                        10 mM 
Adjust pH to 7.4 with HCl, sterilize by passing through a 0.2 μm filter, prepare 4 ml aliquots, 
and store at - 20°C for several months. Before use, add 160 μl of Complete Protease Inhibitor 
Cocktail (final concentration 1×) per aliquot of Washing Buffer. 
 
 
2.9 Whole-lysosome patch clamp recording 
For whole-lysosome planar patch recordings, the Port-a-Patch (Nanion Technologies) was 
used. Lysosomes were enlarged with the treatment of 1 μM vacuolin-1 overnight (102, 119, 123, 
124). The planar patch-clamp technology combined with a pressure control system and 
microstructured glass chips containing an aperture of around 1μm diameter (resistances of 10-15 
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MΩ) (Nanion Technologies). Currents were recorded using an EPC-10 patch-clamp amplifier 
and PatchMaster acquisition software (HEKA). Data were digitized at 40 kHz and filtered at 2.8 
kHz. For all planar patch-clamp experiments, salt-agar bridges were used to connect the 
reference Ag/AgCl wire to the bath solution to minimize voltage offsets. Ag/AgCl-coated 
electrodes need to be regularly chloridated in bleach solution approximately 15 min until a black 
AgCl-layer is obvious on the silver wire. Generally, electrodes should be replaced every 2 
months. 
 
It is essential to form a high-resistance seal (gigaseal) with the membrane of the lysosome 
or organelle of interest. Gigaseals are formed usually with the aid of seal enhancer external 
solution (cytoplasmic side) which contains a high concentration of fluoride, whereas the 
intralysosomal solution contains a high concentration of Ca2+. For tight-seal lysosomal patch-
clamp recordings, we added solutions containing high Ca2+ (> 60 mM) on one side of the glass 
chip and solution containing high fluoride at the other side during seal formation. Omitting either 
of the ions from the respective solutions after seal formation caused loss of seal quality and 
patch-clamp stability. Inclusion of fluoride improved patch-clamp sealing and stabilized the cell 
membrane, which resulted in longer, more stable patch-clamp recordings (125).  
 
The membrane potential was held at -60mV, and 500ms voltage ramps from -200 to +100 
mV were applied every 5s. All recordings were obtained at room temperature (21-23℃), and all 
recordings were analyzed using PatchMaster (HEKA) and Origin 6.1 (OriginLab). To dissect 
lysosomal currents from whole-lysosome planar patch-clamp recording, all currents in the 
absence of compounds were subtracted from the currents obtained in the presence of compounds 
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as previously described (102). Liquid junction potential was corrected. The EC50 of graded dose 
response curves were fitted with the Hill equation. 
 
Standard Intralysosomal Solution 
KMSA                     70 mM 
CaMSA                    60 mM 
MgCl2                      2 mM 
HEPES                     10 mM 
Preparation as follows: Adjust pH to 4.6 with MSA, sterilize by passing through a 0.2 µm filter, 
prepare 1 ml aliquots, and store at –20°C for several months. 
 
Standard Extralysosomal Solution 
KMSA                      60 mM 
KF                            60 mM 
HEPES                     10 mM 
Preparation as follows: Adjust pH to 7.2 with KOH, sterilize by passing through a 0.2 µm filter, 
prepare 4 ml aliquots, and store at –20°C for several months. 
 
CaMSA                    2 mM 
Preparation and use as follows: Add CaMSA immediately before starting the measurements to 
avoid precipitation of CaF2. 
 
Seal Enhancer Solution 
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KMSA                     60 mM 
KF                             60 mM 
EGTA                       10 mM 
HEPES                     10 mM 
Preparation as follows: Adjust pH to 7.2 with KOH, sterilize by passing through a 0.2 µm filter, 
prepare 4 ml aliquots, and store at –20°C for several months. 
 
Extralysosomal Bath Solution 
KMSA                      120 mM 
EGTA                       10 mM 
HEPES                      10 mM 
Preparation as follows: Adjust pH to 7.2 with KOH, sterilize by passing through a 0.2 µm filter, 
prepare 1 ml aliquots, and store at –20°C for several months. 
 
2.10 Podocyte-specific Asah1 gene knockout mouse model 
We developed Asah1fl/fl/PodoCre mice and their littermates including WT/WT and 
Asah1fl/fl/WT mice, which were used for in vivo experiments to explore the role of acid 
ceramidase in podocyte function and integrity. Asah1 is a mouse code of AC gene. The Asah1fl/fl 
mice were provided by Dr. Erich Gulbins (Department of Molecular Biology, University of 
Duisburg-Essen); the PodoCre mice were purchased from Jackson Laboratories (Bar Harbor, ME, 
USA). To confirm the specificity of Asah1 gene knockout in podocytes, Asah1fl/fl/PodoCre mice 
were mated with lacZ/EGFP mice (Jackson Laboratories, Bar Harbor, ME, USA) to produce 
Asah1fl/fl/PodoCre+lacZ/EGFP mice. Based on previous studies, lacZ/EGFP mice express β-
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galactosidase (lacZ) throughout embryonic development and adult stages. Cre excision, however, 
removes the lacZ gene, which activates expression of the second reporter, enhanced green 
fluorescent protein (EGFP). To detect the lacZ expression levels in glomeruli, we performed 
lacZ activity assay in which the expression of lacZ was marked by the dark blue staining. 
Podocyte-specific expression of EGFP was detected by confocal microscopy. During 
experiments, all Asah1fl/fl/PodoCre mice and their littermates at different ages or with different 
treatments were placed in metabolic cages and urine samples were collected for 24 hours before 
collecting blood samples, sacrificing, and harvesting tissues for analysis. The Institutional 
Animal Care and Use Committee of Virginia Commonwealth University approved all animal 
protocols. 
 
2.11 Mouse genotyping 
Each mouse used in the in vivo studies was genotyped for the Asah1fl/fl gene and Cre 
recombinase gene to confirm podocyte-specific gene deletion of acid ceramidase α subunit prior 
to use in experiments. Briefly, genomic DNA extracted from the tail was subjected to PCR 
amplification using taq DNA polymerase (Invitrogen, Inc., Grand Island, NY). Using a Bio-Rad 
iCycler, PCR was performed using a validated protocol provided by Jackson Laboratories: 
denaturing the DNA at 94°C for 3 min, followed by a first round of 12 cycles: 94°C for 20 sec, 
64°C for 30 sec (-0.5°C per cycle), 72°C for 35 sec, and then a second round of 25 cycles: 94°C 
for 20 sec, 58°C for 30 sec, 72°C for 35 sec, and a final extension step at 72°C for 2 min. The 
Asah1WT and Asah1fl/fl genes were detected using primers of 5’-
ACAACTGTGTAGGATTCACGCATTCTCC-3’ and 5’-
TCGATCTATGAAATGTCGCTGTCGG-3’. The internal control gene was detected using 
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primers of 5’-CTAGGCCACAGAATTGAAAGATCT-3’ and 5’-
GTAGGTGGAAATTCTAGCATCATCC-3’. The Cre recombinase gene was detected using 
primers of 5’-GCGGTCTGGCAGTAAAAACTATC-3’ and 5’- 
GTGAAACAGCATTGCTGTCACTT-3’. The PCR products were separated by gel 
electrophoresis on a 3% agarose gel, visualized by ethidium bromide fluorescence, and compared 
to a 100 bp DNA ladder (New England Biosystems, Ipswich, MA). 
 
2.12 β-galactosidase staining 
β-galactosidase staining was performed on 8-μm cryosections of mouse kidneys as 
described previously (126). Briefly, adult mice were perfused with 4% paraformaldehyde. 
Tissues were resected and frozen in liquid nitrogen. Eight-micrometer cryosections were cut and 
postfixed with 4% paraformaldehyde for 5 min. The sections were then incubated overnight at 
30°C with X-gal staining solution (1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM 
potassium ferrocyanide, 2 mM MgCl2 in phosphate-buffered saline [PBS]), washed with PBS, 
dehydrated through grades of ethanol and xylene, and mounted. 
 
2.13 Isolation of glomeruli for LC-MS/MS 
For quantitation of ceramide and its products, Asah1fl/fl/PodoCre mice and their littermates 
were used to isolate glomeruli of the kidney as described previously (127, 128). In brief, the 
mice were anesthetized with 2% isoflurane and then the kidneys were perfused with ice-cold 
PBS and harvested. After blood samples were taken, the mice were euthanized. The harvested 
kidneys were hemisected on a sagittal plane and the renal cortex was separated from the medulla, 
chopped into fine pieces, and passed through filters with decreasing pore sizes from 150 to 106 
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μm (USA standard sieve numbers 100 and 140, respectively; Thermo Fisher Scientific, Waltham, 
MA) into a petri dish. The glomeruli were captured on a 70 μm cell strainer (BD Biosciences, 
San Jose, CA), then washed off from the sieve with ice-cold Hank’s solution containing 6% 
BSA, and pelleted for later use to measure ceramide and sphingosine levels by liquid 
chromatography tandem mass spectrometry (LC-MS/MS). 
 
2.14 LC-MS/MS analysis 
Glomeruli were isolated from mice as described above. After homogenization of glomeruli, 
10 ng C12 ceramide was added to homogenate reaction mixture to act as an internal standard. 
Then, the mixture was separated in chloroform/methanol/water (2:2:1.8). After evaporation with 
nitrogen and reconstitution with ethanol/formic acid (99.8:0.2), the samples were ready for LC-
MS/MS assay. The separation of ceramide was performed on a Shumadzu SCL HPLC system 
(Kyoto, Japan) with a C18 Nucleosil AB Column (Macherey-Nagel, Duren, Germany). MS 
detection was carried out using an Applied Bio systems 3200 Q trap with a turbo V source for 
TurbolonSpray (Ontario, Canada). The concentrations of total ceramide, including C14, C16, 
C18, C20, C22, and C24 ceramide, and sphingosine were calculated after normalization with 
glomerular numbers of each sample. The fragment ion obtained with the highest mass-to-charge 
ratio (m/z 264) was selected for quantitative MS detection in the multiple reaction monitoring 
mode. 
 
2.15 In vitro measurement of glomerular permeability 
The glomerular permeability was measured as previously described (129). The mice were 
anesthetized with 2% isoflurane. FITC-dextran (250 kDa; Sigma-Aldrich, St. Louis, MO) at a 
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dose of 75 mg/kg in a 0.9% NaCl solution was injected into the femoral vein. Other fluorescently 
labeled Cy3, Cy5, and rhodamine high-molecular weight dextrans work equally as well. After 3–
5 min, the kidneys were harvested and placed in ice-cold isotonic HBSS (Life Technologies, 
Grand Island, NY) containing 6% BSA (Sigma-Aldrich) and 10 mM HEPES (Sigma-Aldrich), 
pH 7.4. Then, glomeruli were isolated as previously described (127, 128). Briefly, the kidney 
was hemisected on a sagittal plane and the renal cortex was separated from the medulla, chopped 
into fine pieces, and passed through stainless steel filters with decreasing pore sizes from 150 to 
106 μm (USA standard sieve No. 100 and No. 140, respectively, Thermo Fisher Scientific, 
Waltham, MA) into a petri dish. The glomeruli were captured on a 70-μm cell strainer (BD 
Bioscience, San Jose, CA) and washed off of the sieve with ice-cold Hank's solution containing 
6% BSA. The mixture was transferred to a 15-ml tube and stored on ice before the experiment. 
 
A small aliquot (50–100 μl) of the isolated glomeruli was loaded onto a coverslip, 
precoated with poly-l-lysine hydrobromide (10 mg/ml, Sigma-Aldrich), which formed the 
bottom of a fluid exchange chamber (RC-24, Warner Instruments, Hamden, CT). The inflow line 
to the chamber was attached to two peristaltic pumps so that the bath could be rapidly exchanged 
in less than 10 s. The effluent was collected through a vacuum line. The isolated glomeruli were 
imaged using a fluorescent microscope (Nikon TS-100, Nikon Instruments, Melville, NY) 
equipped with a high-sensitivity camera and a 175-Wt Xenon Arc Lamp (Intracellular Imaging, 
Cincinnati, OH) and filter wheel (Excitation/emission: 480/510–550 μm). The glomeruli were 
observed using a low-numerical aperture ×5 lens (Nikon Instruments, Melville, NY) with a large 
depth of field (>50 μm) so that the fluorescence signal from the entire glomerulus could be 
collected. Approximately 30 glomeruli/field were selected for study based on their 
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morphological appearance. A recording area slightly larger than the circumference of the 
glomeruli was defined using Image 1 fluorescent imaging software (Incyte, Cincinnati, OH) so 
that all of the label remains in the recorded volume when the glomeruli expand following a 
reduction in the oncotic pressure of the bath. Glomeruli poorly labeled or too bright with 
intensities near the saturation level of the camera were not chosen for permeability 
measurements. 
 
Fluorescent intensities were individually recorded, and the values are expressed as the 
percentage of the control intensity measured at time 0 for each glomerulus. There was more 
variation in the time course of the changes in fluorescent intensity between glomeruli than 
between mice of a given strain, so we typically averaged all the individual data and expressed the 
results as number of glomeruli studied per strain or group. After selection of the glomeruli to be 
studied, the chamber was perfused at 0.5 ml/min with a solution containing 6% BSA, and 
baseline fluorescent signals were continuously recorded using a high speed wavelength 
switching fluorescent microscopic system. The bath solution was then switched to one 
containing 4% BSA and the fluorescent signals from the glomeruli were recorded for an 
additional 3-5 minutes. The initial fluorescence value (time 0) was converted to 100%, and the 
subsequent values were expressed as a percentage of the initial value. 
 
2.16 Immunohistochemistry 
Kidneys were embedded with paraffin and 5 mm sections were cut from the embedded 
blocks. After heat-induced antigen retrieval, washing with 3% H2O2, and 30 min blocking with 
fetal bovine serum, slides were incubated with primary antibody diluted in PBS with 4% fetal 
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bovine serum. Anti-α-dystroglycan antibody and anti-β-dystroglycan antibody were used as 
primary antibodies in this study. After incubation with primary antibody overnight, the sections 
were washed in PBS and incubated with biotinylated IgG (1:200) for 1 h and then with 
streptavidin-HRP for 30 min at room temperature. Fifty microliters of DAB were added to each 
kidney section and stained for 1 min. After washing, the slides were counterstained with 
hematoxylin for 5 min. The slides were then mounted and observed under a microscope in which 
photos were taken (130). 
 
2.17 Measurements of urinary protein and albumin excretions 
Total urinary protein excretion was determined spectrophotometrically using the Bradford 
assay (Sigma), and urinary albumin excretion was measured using a commercially available 
mouse albumin ELISA kit (Bethyl Laboratories, Montgomery, TX). 
 
2.18 Glomerular morphological examination 
Renal tissues were fixed with a 10% formalin solution, paraffin-embedded, and stained 
with periodic acid–Schiff (PAS). Renal morphology was observed using a light microscope, and 
glomerular sclerosis was assessed semiquantitatively and expressed as glomerular damage index 
(GDI) (131, 132). Fifty glomeruli per slide were counted and scored as 0, 1, 2, 3, or 4, according 
to 0, <25, 25–50, 51–75, or >75% sclerotic changes, respectively, across a longitudinal kidney 
section. The GDI for each mouse was calculated by the formula ((N1 ×1) + (N2 ×2) + (N3 ×3) + 
(N4 ×4))/n, where N1, N2, N3, and N4 represent the numbers of glomeruli exhibiting grades 1, 
2, 3, and 4, respectively, and n is the total number of glomeruli scored. 
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2.19 Statistical analysis 
All results were expressed as the arithmetic mean ± SEM; n represents the number of 
independent experiments. Data obtained from multiple animal or experimental groups were 
tested for significance using one- or two-way ANOVA, and a paired and unpaired Student’s t-
test was used for two animal or experimental groups. The glomerular damage index was 
analyzed for statistical significance using a nonparametric Mann-Whitney rank sum test and a χ2 
test was used to determine the significance of ratio and percentage data. Results with p<0.05 
were considered statistically significant. 
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CHAPTER THREE 
Podocyte dedifferentiation induced by lysosome dysfunction and associated autophagic 
deficiency 
 
3.1 Enhanced podocyte dedifferentiation by lysosome function inhibition 
To determine whether lysosome function inhibition has effects on podocyte 
dedifferentiation, Western blot analysis was performed before and after inhibition of lysosome 
function by either Baf A1 (Baf), a well-known lysosome function inhibitor through its inhibitory 
effect on V-ATPase or siRNA of this enzyme. As shown in Fig. 2A and 2B, when podocytes 
were treated with Baf, the epithelial markers P-cad and ZO-1 decreased significantly, while the 
mesenchymal markers FSP-1 and α-SMA increased markedly. Similarly, V-H-ATPase siRNA 
transfection (siv-A) decreased P-cad and ZO-1 but increased FSP-1 and α-SMA significantly in 
podocytes (Fig. 2C and 2D). It is clear that the ratio of epithelial markers vs. mesenchymal 
markers was significantly reduced during lysosome function inhibition, suggesting a large 
enhancement of dedifferentiation in podocytes. 
 
3.2 Confocal microscopy of podocyte dedifferentiation during lysosome function 
inhibition 
The effects of lysosome functional inhibition on podocyte dedifferentiation were further 
detected using confocal microscopy. As shown in Fig. 3A, under basal condition podocytes were 
enriched with P-cadherin and ZO-1. When these podocytes were treated with Baf, both P-
cadherin and ZO-1 fluorescent staining were significantly reduced. As shown in overlaid cell 
images (OL in left panels of Fig. 3A), there were much less co-colocalized signals of podocin 
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with ZO-1 or P-cad in Baf-treated podocytes compared with control podocytes. In contrast, FSP-
1 and α-SMA staining increased by Baf as shown by enhanced co-localization of podocin with 
both markers (right panels of Fig. 3A). In podocytes transfected with V-ATPase siRNA (siv-A), 
detected epithelial marker and mesenchymal marker stainings were similar to that shown in Baf-
treated podocytes, decreases in epithelial marker and increases in mesenchymal markers (Fig. 
3B). 
 
3.3 Deficiency of autophagic flux during lysosome function inhibition 
Given the role of autophagy in podocyte differentiation, we tested whether enhanced 
podocyte dedifferentiation due to lysosome function inhibition is associated with deficient 
autophagy. Fig. 4A shows representative gel documents of Western blot using antibodies against 
LC3B, Lamp-1 and p62. Under basal condition and co-treatment of podocytes with rapamycin 
(RPM, an autophagy inducer) or 7-keto (an autophagy stimulator), the protein levels of both 
LC3B-II and p62 (two autophagosome markers) significantly increased by Baf, while Lamp-1, a 
lysosome membrane marker was not changed. As shown in Fig. 4B, lysosome function inhibition 
mainly increased LC3II because the ratio of LC3B-II vs. LC3B-I was largely increased by Baf, 
which were similar under control condition and with stimulation of autophagosome formation by 
RPM or 7-keto. The increased LC3BII level was accompanied by accumulation of p62 in 
podocytes (Fig. 4C). However, the Lamp-1 level was not significantly changed by Baf (Fig. 4D). 
 
3.4 Attenuation of podocyte dedifferentiation by Sp-1 inhibition of autophagosome 
formation 
 30 
To further determine the role of autophagosome accumulation in podocyte dedifferentiation 
enhanced by lysosome function inhibition, we examined the effects of selective autophagosome 
formation inhibitor, Sp-1 on Baf-enhanced podocyte dedifferentiation. As shown in Fig. 5A, a 
representative Western blot gel document showed that Baf dramatically increased the LCB-II 
level. In the presence of Sp-1, the effects of Baf on the LCBII level were largely weakened. As 
summarized in Fig. 5B, the ratio of LC3B-II vs. LC3B-I was significantly increased by Baf. 
However, this increase in Baf-induced autophagosome accumulation was significantly attenuated 
by Sp-1. Moreover, Baf-induced p62 accumulation was markedly inhibited by Sp-1 as shown in 
Western gel document (Fig. 5C). Densitometric analysis showed that lysosome function 
inhibition by Baf led to a significant accumulation of p62 in podocytes, which was remarkably 
lessened by Sp-1 (Fig. 5D). As shown in Fig. 5E, interestingly, enhanced podocyte 
dedifferentiation by Baf as shown by decrease in P-cad and increase in α-SMA was obviously 
attenuated by Sp-1. The ratio of P-cad to α-SMA, a podocyte dedifferentiation index, 
significantly decreased in Baf-treated podocytes. In the presence of Sp-1, P-cadherin to α-SMA 
ratio was significantly reduced (Fig. 5F). 
 
3.5 Failure of Nrf2 gene silencing to alter podocyte dedifferentiation enhanced by 
lysosome function inhibition 
Mechanistically, we first tested the possibility of p62-regulated Nrf2 signaling pathway to 
participate in the enhancement of podocyte dedifferentiation by lysosome function inhibition. 
Fig. 6A shows representative Western blot gel documents illustrating the changes in P-cad, α-
SMA and p62 induced by Baf before and after Nrf2 gene silencing (siNrf). The level of P-cad 
was markedly decreased, while p62 increased in Baf-treated podocytes. These Baf-induced 
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changes in podocyte dedifferentiation markers in associated with increase in p62 were not altered 
by Nrf2 gene silencing. As shown in Fig. 6B, Baf significantly decreased the ratio of P-cad and 
α-SMA, a podocyte dedifferentiation index. However, Nrf2 gene silencing did not alter the ratio 
of P-cad to α-SMA. In addition, Baf-induced significant accumulation of p62 was also not 
altered by Nrf2 siRNA (Fig. 6C). 
 
3.6 No changes in enhanced podocyte dedifferentiation by inhibition of NF-κB-mediated 
transcriptional regulation 
Given the role of NF-κB-mediated transcriptional regulation in cell dedifferentiation and its 
association with p62, we tested whether inhibition of its activity alters podocyte dedifferentiation 
enhanced by lysosome function inhibition. Representative Western blot gel documents in Fig. 7A 
showed that the level of P-cad remarkably decreased, but p62 was increased in Baf-treated 
podocytes. These Baf-induced changes in podocyte dedifferentiation markers as well as p62 
were same before and after treatment with a NF-κB inhibitor, Bortezomib (Bor). As summarized 
in Fig. 7B, Baf significantly decreased the ratio of P-cad vs. α-SMA, the podocyte 
dedifferentiation index, which was not altered by pharmacological inhibition of NF-κB activity. 
Furthermore, Baf-induced significant accumulation of p62 remained same even though NF-κB 
activity was inhibited (Fig. 7C). We also inhibited NF-κB-mediated transcriptional regulation by 
gene silencing to further confirm whether this transcription factor is involved in Baf-enhanced 
podocyte dedifferentiation. As shown in Fig. 7D, 7E and 7F, the effect of NF-κB gene silencing 
(siNF-kB) on Baf-enhanced podocyte dedifferentiation was similar to its pharmacological 
inhibition, without effects on decreases in the ratio of P-cad vs. α-SMA and p62 accumulation in 
podocytes. 
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3.7 Enhancement of podocyte dedifferentiation by inhibition of CDK1 
Another signaling pathway being tested is whether inhibition of CDK1 activity and 
expression alters Baf-induced enhancement of dedifferentiation in podocytes. It has been 
reported that phosphorylation of p62 regulates exit from cell cycle or cell arrest during cell 
mitosis and that reduced phosphorylation of p62 leads to a faster exit from cell mitosis, 
controlling cell dedifferentiation and tumorigenesis (133). In Fig. 8, panel A shows 
representative Western blot gel documents, depicting that the level of P-cad remarkably 
decreased, but α-SMA and p62 increased in Baf-treated podocytes. Similar to Baf, CDK1 
inhibitor, a quinolinyl thiazolinone derivative, RO-3306 (RO) also decreased the level of P-cad 
markedly, but increased α-SMA and p62 in podocytes. In the presence of RO, Baf-induced 
changes in podocyte dedifferentiation markers were almost same as that observed in the absence 
of RO. However, RO was without effect on p62 level before and after stimulation of Baf. Fig. 8B 
presents summarized results showing that the ratio of P-cad to α-SMA was significantly reduced 
by both Baf and RO. Moreover, the inhibition of CDK1 by RO had no effect on the p62 level in 
podocytes under control condition and upon Baf treatment (Fig. 8C). To further confirm the role 
of CDK1 in enhancement of podocyte dedifferentiation, we used its siRNA to test whether gene 
silencing of CDK1 alters podocyte dedifferentiation. As shown in Fig. 8D, 8E and 8F, CDK1 
siRNA (siCDK1) had similar effects on podocyte dedifferentiation to CDK1 inhibitor-RO, 
enhancing podocyte dedifferentiation under control condition without further influence on Baf-
induced enhancement of podocyte dedifferentiation. It was also without effects on p62 levels in 
podocytes with or without treatment of Baf. 
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3.8 Reduction of p62 phosphorylation during lysosome function inhibition 
Further experiments were designed to determine whether reduced p62 phosphorylation 
occurs due to lysosome function inhibition. As shown in Fig. 9A, Western blot gel documents 
show that CDK1 inhibitor RO markedly decreased phosphorylated p62 even though it had no 
effect on total p62 level in podocytes. However, Baf mainly led to p62 accumulation, but it had 
no effect on phosphorylation of p62. By calculation, the ratio of phosphorylated p62 to total p62 
was found reduced significantly by both RO and Baf, suggesting that the relative reduction of 
phosphorylated p62 may be involved in the control of podocyte dedifferentiation (Fig. 9B). We 
also conducted additional experiments to silence CDK1 gene in order to confirm the role of 
decreased phosphorylated p62 in podocyte dedifferentiation. As presented in Fig. 9C, similar to 
RO, CDK1 siRNA reduced phosphorylated p62, but had no effects on total p62 level. As 
summarized in Fig. 9D, this CDK1 siRNA reduced the ratio of phosphorylated p62 to total p62, 
which was similar to the effects of Baf. 
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Fig. 2. Enhanced podocyte dedifferentiation by lysosome function inhibition. Podocytes 
were stimulated by Baf (5 µM) for 12 hours or transfected with v-Ca2+-ATPase siRNA (10 
nM) for 24 hours. A. Representative gel documents showing the expression of ZO-1 and P-
cadherin (P-cad) as epithelial markers and the expression of α-SMA and FSP-1 as 
mesenchymal markers in different groups. B. Summarized data showing the expression of 
ZO-1 and P-cadherin as epithelial markers and the expression of α-SMA and FSP-1 as 
mesenchymal markers, quantitated as a ratio of detected specific protein band vs. β-actin as 
loading control (n=3-5). C. Representative gel documents showing the expression of ZO-1 
and P-cadherin as epithelial markers and the expression of α-SMA and FSP-1 as 
mesenchymal markers in different groups. D. Summarized data showing the expression of 
ZO-1 and P-cadherin as epithelial markers and the expression of α-SMA and FSP-1 as 
mesenchymal markers, quantitated as a ratio of detected specific protein band vs. β-actin as 
loading control (n=3-5). * P<0.05 vs. Ctrl. Ctrl: Control; Baf: Baf; Scra: scramble RNA; siv-
A: V-H-ATPase siRNA. 
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Fig. 3. Confocal microscopy of podocyte dedifferentiation during lysosome function 
inhibition. A. Images showing double-immunostained podocytes for epithelial markers, P-
cadherin (p-cad) and ZO-1 (Alex555, red color) or mesenchymal markers, α-SMA and FSP-1 
(Alex555, red color) with podocyte marker, podocin (Alex488, green color) in different 
groups (n=5). B. Images showing double-immunostained podocytes for epithelial markers, P-
cadherin and ZO-1 (Alex555, red color) or mesenchymal markers, α-SMA and FSP-1 
(Alex555, red color) with podocyte marker, podocin (Alex488, green color) in different 
groups (n=4). Ctrl: Control; Baf: Baf; Scra: scramble RNA; siv-A: V-H-ATPase siRNA; OL: 
Overlaid. 
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Fig. 4. Deficiency of autophagic flux during lysosome function inhibition. Podocytes were 
cultured for 24 hrs with rapamycin (100 nM) or 7-keto cholesterol (5 µg/ml) in the absence or 
presence of Baf A1 (10 nM). A. Representative gel documents showing the expression of 
LC3B-I, LC3B-II, p62 as autophagosome markers and Lamp-1 as lysosome marker in 
different groups. B. Summarized data showing expression of LC3B-I and LC3B-II, 
quantitated as a ratio of LC3B-II band over LC3B-I band (n=4). C. Summarized data showing 
expression of p62, quantitated as a ratio of detected specific protein band vs. β-actin as 
loading control (n=4). D. Summarized data showing expression of Lamp-1, quantitated as a 
ratio of detected specific protein band vs. β-actin as loading control (n=4). * P<0.05 vs. Ctrl: 
Control; Baf: Baf; Vehl: vehicle; RPM: Rapamycin; 7-Keto: 7-Ketocholesterol. 
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Fig. 5. Attenuation of podocyte dedifferentiation by Sp-1 inhibition of autophagosome 
formation. A. Representative gel documents showing the expression of LC3B-I and LC3B-II 
as autophagosome markers in different groups. B. Summarized data showing expression of 
LC3B-I and LC3B-II, quantitated as a ratio of LC3B-II band over LC3B-I band (n=3). C. 
Representative gel documents showing the expression of p62 as autophagosome marker in 
different groups. D. Summarized data showing expression of p62, quantitated as a ratio of 
detected specific protein band vs. β-actin as loading control (n=3). E. Representative gel 
documents showing the expression of P-cadherin, α-SMA in different groups. F. Summarized 
data showing expression of P-cadherin and α-SMA, quantitated as a ratio of P-cadherin band 
over α-SMA band (n=3-4). * P<0.05 vs. Ctrl; # P<0.05 vs. Baf. Ctrl: Control; Baf: Baf; Vehl: 
Vehicle; Sp-1: Spautin-1. 
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Fig. 6. Failure of Nrf2 gene silencing to alter podocyte dedifferentiation enhanced by 
lysosome function inhibition. A. Representative gel documents showing the expression of P-
cadherin, α-SMA and p62 in different groups. B. Summarized data showing expression of P-
cadherin and α-SMA, quantitated as a ratio of P-cadherin band over α-SMA band (n=3-4). C. 
Summarized data showing expression of p62, quantitated as a ratio of detected specific 
protein band vs. β-actin as loading control (n=3-4). * P<0.05 vs. Ctrl. Ctrl: Control; Baf: Baf; 
Scra: scramble RNA; siNrf: Nrf2 siRNA. 
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Fig. 7. No changes in enhanced podocyte dedifferentiation by inhibition of NF-κB-
mediated transcriptional regulation. A. Representative gel documents showing the 
expression of P-cadherin, α-SMA and p62 in different groups. B. Summarized data showing 
expression of P-cadherin and α-SMA, quantitated as a ratio of P-cadherin band over α-SMA 
band (n=5). C. Summarized data showing expression of p62, quantitated as a ratio of detected 
specific protein band vs. β-actin as loading control (n=5). D. Representative gel documents 
showing the expression of P-cadherin, α-SMA and p62 in different groups. E. Summarized 
data showing expression of P-cadherin and α-SMA, quantitated as a ratio of P-cadherin band 
over α-SMA band (n=5). F. Summarized data showing expression of p62, quantitated as a 
ratio of detected specific protein band vs. β-actin as loading control (n=4). * P<0.05 vs. Ctrl. 
Ctrl: Control; Baf: Baf; Bor: Bortezomib; Scra: scramble RNA; siNF κB: NF κB siRNA. 
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Fig. 8. Enhancement of podocyte dedifferentiation by inhibition of CDK1. A. 
Representative gel documents showing the expression of P-cadherin, α-SMA and p62 in 
different groups. B. Summarized data showing expression of P-cadherin and α-SMA, 
quantitated as a ratio of P-cadherin band over α-SMA band (n=5). C. Summarized data 
showing expression of p62, quantitated as a ratio of detected specific protein band vs. β-actin 
as loading control (n=9). D. Representative gel documents showing the expression of P-
cadherin, α-SMA and p62 in different groups. E. Summarized data showing expression of P-
cadherin and α-SMA, quantitated as a ratio of P-cadherin band over α-SMA band (n=5). F. 
Summarized data showing expression of p62, quantitated as a ratio of detected specific 
protein band vs. β-actin as loading control (n=7). * P<0.05 vs. Ctrl. Ctrl: Control; Baf: Baf; 
RO: RO-3306; Scra: scramble RNA; siCDK1: CDK1 siRNA. 
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Fig. 9. Reduction of p62 phosphorylation during lysosome function inhibition. A. 
Representative gel documents showing the expression of p62 and p-p62 in different groups. 
B. Summarized data showing expression of p62 and p-p62, quantitated as a ratio of p-p62 
band over p62 band (n=5). C. Representative gel documents showing the expression of p62 
and p-p62 in different groups. D. Summarized data showing expression of p62 and p-p62, 
quantitated as a ratio of p-p62 band over p62 band (n=4). * P<0.05 vs. Ctrl. Ctrl: Control; 
Baf: Baf; RO: RO-3306; Scra: scramble RNA; siCDK1: CDK1 siRNA. 
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CHAPTER FOUR 
Contribution of altered ceramide metabolism via acid ceramidase to lysosome dysfunction 
through reduced TRPML1 channel activity 
 
4.1 Lysosome trafficking and fusion to autophagosome regulated by acid ceramidase in 
podocytes 
The results presented in chapter 3 confirmed that normal lysosome function is essential to 
the autophagic flux and thereby for podocyte differentiation. Pharmacological and genetic 
interventions to induce lysosome dysfunction led to accumulation of autophagosomes and 
thereby activated podocyte dedifferentiation. The next question we tried to answer is whether 
there is any physiological regulatory system that regulates lysosome functions in podocytes and 
thereby controls the differentiation of dedifferentiation of these cells. In previous studies from 
our laboratory and by others, ceramide metabolism in lysosomes was been demonstrated to play 
an important role in the control of lysosome function including the lysosome fusion to 
membrane, organelles and Ca2+ release (112, 121, 134-136). Therefore, we hypothesized that 
ceramide production or metabolism may contribute to the regulation of lysosome function, 
autophagic flux and differentiation of podocytes. A deficiency of ceramide metabolism may 
result in increased level of ceramide in these cells and thereby cause lysosome dysfunction, 
autophagic deficiency and dedifferentiation. 
 
To test this hypothesis, we directly observed the role of acid ceramidase, an enzyme for 
catabolism of ceramide to produce sphingosine in the lysosome trafficking and fusion to 
autophagosome in living podocytes. In these experiments, both LC3B-GFP and Lamp-1-RFP 
 43 
gene constructs were introduced into podocytes to visualize lysosome (red puncta) and 
autophagosome (green puncta). Co-localization of LC3B-GFP and Lamp-1-RFP yields yellow 
puncta, indicating the fusion of lysosome and autophagosome. As shown in Fig. 10, only a few 
yellow puncta were detected in living podocytes under control condition. When podocytes were 
treated with an autophagy activator, rapamycin, which has been reported to enhance the entire 
autophagic process including autophagosome formation and autophagic flux, the number of 
yellow puncta markedly increased and the co-localization coefficient of LC3B-GFP with Lamp-
1-RFP was significantly increased, indicating enhanced fusion of autophagosomes and 
lysosomes. On the contrary, the fusion of lysosome and autophagosome was blocked by Baf A1, 
a V-ATPase inhibitor. Similarly, inhibition of AC activity by carmofur markedly decreased the 
yellow puncta in these living podocytes. These results suggest that lysosome AC activity is 
indeed involved in the regulation of lysosome trafficking and fusion to autophagosomes. 
 
4.2 Lysosome trafficking and fusion to MVBs regulated by acid ceramidase in podocytes 
We also used another marker to measure lysosome trafficking in podocytes, which was to 
observe the trafficking of lysosome and fusion to multivesicular bodies (MVBs), which 
represents another important lysosome function in the regulation of intracellular vesicle 
trafficking or exosome excretion (137-139). In these experiments, we observed the trafficking 
and fusion of lysosomes to MVBs in podocytes using confocal microscopy. As shown in Fig. 
11A, colocalization of MVB marker, VPS16 (Alex 488, green fluorescence) and lysosome 
marker, Lamp-1 (Alex 555, red fluorescence) yielded yellow puncta, indicating the fusion of 
lysosome and MVB. Compared with vehicle group, podocytes with inhibition of AC by 
carmofur also markedly inhibited lysosome trafficking and fusion to MVB. However, such 
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inhibition was totally reversed by pretreatment of podocytes with AC inducer genistein or 
sphingosine, an AC product of ceramide. Similarly, colocalization of another MVB marker 
Annexin-II (Alex 488, green fluorescence) and Lamp-1 (Alex 555, red fluorescence) was 
remarkably decreased by carmofur. Moreover, enhancement of AC activity by genistein or 
addition of sphingosine totally reversed the reduction of lysosome trafficking and fusion to MVB 
in podocytes (Fig. 11B). 
 
4.3 TRPML1 channel-mediated Ca2+ release detected by GCaMP3 in podocytes 
To explore the mechanisms by which ceramide metabolism regulates lysosome trafficking, 
we performed another series of experiments to address the role of lysosome Ca2+ release in the 
regulation of lysosome trafficking. The scientific premise of these experiments is that TRPML1 
channel-mediated Ca2+ release may be an important driving force for lysosome trafficking, 
which was demonstrated by a number of previous studies (112, 140, 141). We measured 
lysosomal Ca2+ release in intact podocytes using GCaMP3, a single-wavelength genetically 
encoded Ca2+ indicator, to the cytoplasmic amino terminus of TRPML1 (Fig. 12A). When 
transfected into podocytes, GCaMP3-TRPML1 (GCaMP3-ML1) was mainly localized in 
lysosomes. To determine the specificity of the GCaMP3-ML1 fluorescence signal, we tested a 
specific TRPML1 channel agonist ML-SA1 and found that GCaMP3 fluorescence (F470) 
responded to ML-SA1 in podocytes. As shown in Fig. 12B, confocal microscopy detected that 
ML-SA1 remarkably increased GCaMP3 fluorescence in podocytes compared with control 
condition. Maximal response of GCaMP3 to Ca2+ signals was induced by ionomycin, a selective 
calcium ionophore. These data confirmed the specificity of GCaMP3-ML1 fluorescence as Ca2+ 
responsive signal in podocytes. 
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4.4 Characterization of lysosome-derived Ca2+ release through TRPML1 channel 
Next, we investigated whether TRPML1 channel-mediated Ca2+ release detected by 
GCaMP3 is derived from lysosomes in podocytes. A fluorescent microscopic imaging system 
with high speed wave-length switching was used to dynamically and continuously monitor the 
GCaMP3 fluorescence signal in podocytes. The representative curves of GCaMP3 fluorescence 
recording are shown in Fig. 13A. To induce Ca2+ release from lysosomes, we used glycyl-L-
phenylalanine 2-naphthylamide (GPN), a cathepsin C substrate that induces osmotic lysis of 
lysosomes, which can be used to test whether emptying lysosome Ca2+ storage can reduce or 
abolish GCaMP3 detected Ca2+ signals. It was found that early addition of GPN triggered a 
remarkable increase in GCaMP3 fluorescence in podocytes, which was followed by a much 
lower GCaMP3 fluorescence signal induced by late addition of ML-SA1 (Fig. 13A). On the 
other hand, early addition of ML-SA1 induced a rapid increase in GCaMP3 fluorescence and a 
following addition of GPN only induced a small GCaMP3 fluorescence signal in podocytes (Fig. 
13B). These data confirmed that the resource of TRPML1 channel-mediated Ca2+ release 
detected by GCaMP3 was lysosomes in podocytes, which is dependent on lysosome Ca2+ stores. 
 
4.5 Inhibition of AC blocked Ca2+ release through TRPML1 channel in podocytes 
To determine the role of AC in the regulation of TRPML1 channel activity in podocytes, 
carmofur was used to inhibit AC activity before addition of ML-SA1, a potent synthetic agonist 
for TRPML1 channel, to Ca2+-free external solution. As shown in Fig. 14, ML-SA1 induced 
rapid elevation of GCaMP3 fluorescence in podocytes after treatment with vehicle. However, 
pre-treatment with carmofur totally blocked ML-SA1-induced Ca2+ release through TRPML1 
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channel in podocytes, indicating that normal function of AC is essential for TRPML1 channel 
activity in podocyte lysosomes. 
 
To further confirm this view, sphingosine or sphingosine-1-phosphate (S1P) as AC 
metabolits of ceramide was used to treat podocytes during GCaMP3 fluorescence recording. As 
shown in Fig. 15, it was found that sphingosine triggered remarkable increase in lysosome Ca2+ 
as shown by increased GCaMP3 fluorescence in podocytes. On the other hand, S1P had no 
effects on TRPML1 channel activity in podocytes. Considering that sphingosine is AC product 
of ceramide, these data demonstrate that activation of AC and consequent production of 
sphingosine contribute to TRPML1 channel-mediated Ca2+ release from lysosome in podocytes. 
 
4.6 Establishing patch clamp recording using Port-A-Patch 
To directly record lysosome Ca2+ channels or TRPML1 channels, the Port-A-Patch system- 
a novel automatic patch clamp technique was used for whole-lysosome patch clamping. At 
beginning, to establish an appropriate condition for podocyte patch clamping using this new 
system, we first performed whole-cell patch clamp experiments on the cell membrane of cultured 
podocytes. Using pannexin-1 (PANX1) channel, an ATP release channel as a prototype channel 
in podocyte, we successfully tested this new patch clamping system in podocytes and then 
extend such channel recording system into lysosomes. 
 
We first characterized the expression of PANX1 in murine podocytes. Western blot 
analysis demonstrated that PANX1 was highly expressed in cultured murine podocytes, while 
both PANX2 and PANX3 were undetectable in these cells (Figs. 16A and 16B). Using real time 
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RT-PCR, we found high level of PANX1 mRNA in podocytes (data not shown). Also, abundant 
expression of PANX1 was confirmed in renal glomeruli of C57BL/6J WT mice using 
immunohistochemistry (Fig. 16C). However, we failed to observe the immunohistochemical 
staining of PANX2 or PANX3 in renal glomeruli of these mice. In addition, using confocal 
microscopy it was found that red fluorescence of PANX1 highly colocalized with green 
fluorescence of podocin (Fig. 16D) or nephrin (Fig. 16E) in podocytes in vitro or in vivo, which 
further confirmed the expression of PANX1 in podocytes. 
 
After confirmation of pannexin-1 (PANX1) channel expression in podocytes, we next 
confirmed the activity of PANX1 as a large transmembrane channel in podocytes. Fig. 17A 
shows representative recordings of this large voltage-gated outward current at holding potentials 
from -70 to 80 mV under the Cs+in/Na+out gradient of the cells. Fig. 17B summarizes the 
relationship of holding potential and channel current amplitude. It is clear that the channel 
currents increased with the elevation of holding potential and the whole-cell current was 
~283.9±10.9 pA/pF at +80 mV. Pharmacologically, these podocyte membrane currents were 
blocked with selective PANX1 inhibitors, carbenoxolone (CBX) and probenecid (PBNC) by 
81.0±2.6% and 73.8±2.1% of control, respectively. The sensitivity of whole-cell currents to CBX 
and PBNC was well detected at negative voltage, signifying the voltage-gated property of these 
currents and further demonstrating the contribution of PANX1 to these currents. 
 
As another important nature of PANX1, anion permeability was also determined by the 
substitution of extracellular chloride for a carrying anion for PANX1 currents. During whole-cell 
current recording, 140 mM NaCl, 4 mM KCl, 1 mM MgCl2, and 2 mM CaCl2 were substituted 
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for 140 mM Na-aspartate, 4 mM K-aspartate, 1 mM Mg-aspartate2, 2 mM Ca-aspartate. As 
shown in Fig. 18A, the replacement of chloride with aspartate (131 Da) remarkably decreased 
the whole-cell currents and shifted the reversal potential of PANX1 channel to the right. Similar 
data was obtained when we replaced chloride with gluconate (195 Da) in the external solution 
(Fig. 18C). Restoration of extracellular chloride totally recovered the whole-cell currents and the 
reversal potential of PANX1 channel in podocytes. Summarized data demonstrated significant 
decrease in whole-cell currents by chloride replacement (Fig. 18B and Fig. 18D). Altogether, 
these observations confirmed that PANX1 is a voltage-gated transmembrane channel with anion 
permeability in podocytes. 
 
4.7 Regulation of PANX1 channel activity by adipokines 
Given the stimulatory role of extracellular ATP in inflammation and chronic low-grade 
inflammation as a hallmark of obesity, we tested whether visfatin, a pro-inflammatory adipokine 
from fat cells activates PANX1 channel activity to release ATP. As shown in Fig. 19A, addition 
of visfatin into the bath solution remarkably increased whole-cell PANX1 currents. Summarized 
data showed that visfatin at 0.25-1 µg/mL significantly enhanced PANX1 channel activity in a 
dose-dependent manner (Fig. 19B). When podocytes were pretreated with CBX, visfatin-induced 
enhancement of PANX1 channel activity was almost completely blocked (Fig. 19C and Fig. 
19D). 
 
Since previous studies have reported that adiponectin, a protective adipokine, can increase 
intracellular ATP content, further experiments were designed to determine whether these 
channels can be inhibited by adiponectin. As shown in Fig. 20A, the representative recordings 
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showed that addition of adiponectin into the extracellular solution remarkably decreased whole-
cell currents of PANX1. Fig. 20B summarizes the results showing that adiponectin at 2.5-10 
µg/mL significantly inhibited the PANX1 channel activity in a dose-dependent manner. When 
the dose of adiponectin reached 10 µg/mL, the activity of PANX1 channel decreased to 
29.4±5.3% of control, a level similar to the effects of CBX and PBNC. 
 
These experiments demonstrate that podocytes express PANX1 channels on their cell 
membrane, which may be important for the regulation of ATP release under different 
physiological and pathological conditions. Importantly, we found that a Port-A-Patch system can 
be used to automatically patch clamp podocytes for recording of podocytes. To our knowledge, 
these results represent the first use of Port-a-Patch for podocyte PANX1 channels recording to 
show the regulatory action of adipokines on the activity of this channel. Importantly, the 
establishment of such cell patching and recording system provides an important tool for us to 
study intracellular organellar channels given the potential for automatic patching of single 
lysosome without use of glass pipettes. 
 
4.8 Characterization of enlarged lysosomes isolated from podocytes 
For patch clamp studies of single lysosomes from podocytes using the Port-A-Patch 
system, we need to isolate and purify lysosomes from these cells. To isolate lysosomes, we first 
treated podocytes with vacuolin-1 to enlarge lysosomes and then isolated enlarged lysosomes 
from podocytes for whole-lysosome patch clamp recording. As shown in Fig. 21A, a lysosome 
isolated from podocytes was confirmed by differential interference contrast (DIC) microscopy 
compared to podocytes in size. Isolated lysosomes loaded with LysoTracker were also confirmed 
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with green fluorescence that indicates the low pH of lysosome lumen. In addition, the purity of 
isolated lysosomes was confirmed by flow cytometry. Fig. 21B showed that isolated lysosomes 
loaded with LysoTracker shifted to the area with high fluorescence intensity. Quantification of 
the data in Fig. 21B indicated very high purity of isolated lysosomes. 
 
After confirmation of integrity and purity of isolated lysosomes, the whole-lysosome patch 
clamp approach was adopted to characterize the properties of TRPML1 channel in isolated 
lysosomes. As shown in Fig. 22, bath application of ML-SA1 induced TRPML1 channel-
mediated Ca2+ releasing current from lysosome in a dose-dependent manner. In the presence of 
20 µM ML-SA1 in the bath solution, the whole-lysosome current was -333.18±18.83 pA at -200 
mV with positive reversal potentials. These data demonstrated the normal function of TRPML1 
channel in isolated lysosomes from podocytes. 
 
4.9 Enhancement of TRPML1 channel activity by sphingosine 
To further confirm the role of AC in TRPML1 channel-mediated Ca2+ release from 
lysosomes, the effects of sphingolipids associated with AC, sphingomyelin (SM), ceramide 
(Cer), and sphingosine (Sph), on TRPML1 channel currents were tested by whole-lysosome 
patch clamp recording. As shown in Fig. 23, ML-SA1-induced Ca2+ enhancement through 
TRPML1 channels was blocked by sphingomyelin. On the other hand, ceramide had no effects 
on TRPML1 channel-mediated Ca2+ currents induced by ML-SA1. Sphingosine, the AC product 
of ceramide, was found to enhance TRPML1 channel activation in the presence of ML-SA1. 
These results imply that inhibition of AC may reduce sphingosine production, thereby decreasing 
TRPML1 channel activity. It is also possible that reduction of AC activity induces ceramide 
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accumulation in lysosomes, which in turn results in sphingomyelin increase, thereby suppressing 
TRPML1 channel activity. This effect of sphingolipids on TRPML1 channel activity may be a 
cellular mechanistic basis for their regulation of lysosome trafficking, which can be toward 
autophagosomes, MVBs, or SRs (89, 120, 141, 142). 
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Fig. 10. Lysosome trafficking and fusion to autophagosome regulated by acid 
ceramidase in podocytes. Representative images showing the colocalization of LC3B-GFP 
and Lamp-1-RFP in podocytes of various treatment groups (n=3). Vehl: vehicle; Baf: Baf A1; 
Carm: Carmofur; RPM: rapamycin. 
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Fig. 11. Lysosome trafficking and fusion to MVBs regulated by acid ceramidase in 
podocytes. A. Representative images showing the colocalization of VPS16 (green 
fluorescence) and Lamp-1 (red fluorescence) in podocytes of various treatment groups. B. 
Summarized data of colocalization coefficients of VPS16 and Lamp-1 in podocytes of various 
treatment groups (n=4). C. Representative images showing the colocalization of Annexin-II 
(green fluorescence) and Lamp-1 (red fluorescence) in podocytes of various treatment groups. 
D. Summarized data of colocalization coefficients of Annexin-II and Lamp-1 in podocytes of 
various treatment groups (n=4). * P<0.05 vs. Ctrl-Vehl. # P<0.05 vs. Ctrl-Carm. Ctrl: 
Control; Carm: Carmofur; Sph: sphingosine; Gen: Genistein. 
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Fig. 12. TRPML1 channel-mediated Ca2+ release detected by GCaMP3 in podocytes. A. 
GCaMP3-TRPML1 (GCaMP3-ML1) fusion strategy. GCaMP3 is fused to the N-terminus of 
TRPML1. B. Representative micrographs showing the changes of GCaMP3 fluorescence 
upon bath application of ML-SA1 and ionomycin to GCaMP3-ML1-transfected podocytes. 
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Fig. 13. Characterization of lysosome-derived Ca2+ release through TRPML1 channel. 
A. ML-SA1 (20 µM) induced rapid increases in GCaMP3 fluorescence (measured as change 
of GCaMP3 fluorescence ∆F over basal fluorescence F0; ∆F/F0) in podocytes transfected 
with GCaMP3-ML1. Subsequent application of GPN (200 µM) induced smaller responses. 
On the other hand, ML-SA1 induced small responses in GCaMP3-ML1-expressing podocytes 
that had received an application of GPN. Maximal responses were induced by ionomycin (1 
µM) application. B. Summarized data showing ML-SA1-induced responses in podocytes 
transfected with GCaMP3-ML1 after pretreatment with GPN and GPN-induced responses in 
podocytes transfected with GCaMP3-ML1 after pretreatment with ML-SA1. * P<0.05 vs. pre-
treatment with ML-SA1. # P<0.05 vs. pre-treatment with GPN. GPN: glycyl-L-phenylalanine 
2-naphthylamide; Ionom: ionomycin. 
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Fig. 14. Inhibition of AC blocked Ca2+ release through TRPML1 channel in podocytes. 
A. ML-SA1 (20 µM) induced rapid increases in GCaMP3 fluorescence (measured as change 
of GCaMP3 fluorescence ∆F over basal fluorescence F0; ∆F/F0) in podocytes transfected 
with GCaMP3-ML1 after pre-treatment with vehicle. On the other hand, ML-SA1 induced 
small responses in GCaMP3-ML1-expressing podocytes after pre-treatment with Carmofur. 
Maximal responses were induced by ionomycin (1 µM) application. B. Summarized data 
showing ML-SA1-induced responses in podocytes transfected with GCaMP3-ML1 after 
pretreatment with vehicle and ML-SA1-induced responses in podocytes transfected with 
GCaMP3-ML1 after pretreatment with Carmofur. * P<0.05 vs. Vehl-Ctrl. # P<0.05 vs. Vehl-
ML-SA1. Ctrl: control; Vehl: vehicle; Ionom: ionomycin; Carm: Carmofur. 
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Fig. 15. Sphingosine induced Ca2+ release through TRPML1 channel in podocytes. A. 
Sphingosine (20 µM) induced remarkable increases in GCaMP3 fluorescence in podocytes 
transfected with GCaMP3-ML1. On the other hand, S1P had no effects on GCaMP3 
fluorescence in GCaMP3-ML1-expressing podocytes. Maximal responses were induced by 
ionomycin (1 µM) application. B. Summarized data showing responses in podocytes 
transfected with GCaMP3-ML1 induced by sphingosine and S1P. * P<0.05 vs. Ctrl. Ctrl: 
control; Sph: sphingosine; S1P: sphingosine-1-phosphate. 
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Fig. 16. Expression of PANXs in cultured podocytes. A. Representative Western blot gel 
documents and summarized data showing the expressions of PANX1, PANX2, and PANX3 
in cultured podocytes. B. Summarized data showing the expressions of PANX1 in cultured 
podocytes (n=4). C. Immunohistochemical staining of PANX1, PANX2, and PANX3 in 
glomeruli from mice (n=4-5). D. Representative image of confocal microscopy showing the 
colocalization of podocin and PANX1 in cultured podocytes (n=4). E. Representative image 
of confocal microscopy showing the colocalization of nephrin and PANX1 in glomeruli from 
mice (n=6). * p<0.05 vs. 10 µg protein group. PANX: pannexins; OL: overlay. 
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Fig. 17. Recording and pharmacological inhibition of PANX1 channel activity in 
podocytes. Podocytes were held at -50 mV and polarized by 100 ms voltage pulses between -
70 and 80 mV. A. Representative whole-cell currents of podocytes with or without CBX. B. I-
V curves of steady-state currents of podocytes with or without CBX (25 µM) (n=10). C. 
Representative whole-cell currents of podocytes in the presence or the absence of PBNC. D. 
I-V curves of steady-state currents of podocytes in the presence or the absence of PBNC (1 
mM) (n=12). CBX: carbenoxolone; PBNC: probenecid. 
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Fig. 18. Anion permeability of PANX1 channels. PANX1 currents in podocytes were 
recorded with different anion in the external solution. A. Representative whole-cell currents 
of podocytes with chloride or aspartate in the external solution. B. I-V curves illustrating 
shifts of PANX1 current reversal potentials upon replacement of extracellular chloride with 
aspartate (n=5). C. Representative whole-cell currents of podocytes with chloride or gluconate 
in the external solution. D. I-V curves illustrating shifts of PANX1 current reversal potentials 
upon replacement of extracellular chloride with gluconate (n=8). 
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Fig. 19. Concentration-dependent enhancement of PANX1 channel activity by visfatin. 
A. Representative whole-cell currents of podocytes with or without visfatin in the external 
solution. B. I-V curves of steady-state currents of podocytes with or without visfatin in 3 
doses (0.25, 0.5, and 1 µg/mL) in the external solution (n=9). C. Representative whole-cell 
currents of podocytes before and after addition of visfatin to the external solution with CBX. 
D. I-V curves of steady-state currents of podocytes before and after addition of visfatin to the 
external solution with CBX (n=6). The responses were statistically distinguishable (P<0.05 
vs. Control group). Visf: visfatin; CBX: carbenoxolone. 
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Fig. 20. Concentration-dependent inhibition of PANX1 channel activity by adiponectin. 
A. Representative whole-cell currents of podocytes with or without adiponectin in the external 
solution. B. I-V curves of steady-state currents of podocytes with or without adiponectin in 3 
doses (2.5, 5, and 10 µg/mL) in the external solution (n=9). The responses were statistically 
distinguishable (P<0.05 vs. Control group). Adip: adiponectin. 
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Fig. 21. Characterization of lysosomes isolated from murine podocytes. A. Representative 
images of (1) DIC picture of suspended podocyte, (2) DIC picture of isolated lysosome, and 
(3) isolated lysosome stained with LysoTracker. B. Purity of isolated lysosomes detected by 
flow cytometry (n=5). * P<0.05 vs. Unstained group. 
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Fig. 22. Concentration-dependent activation of TRPML1 channel activity by ML-SA1. 
A. Representative whole-lysosome currents enhanced by ML-SA1. B. ML-SA1 enhanced 
TRPML1 channel activity in a concentration-dependent manner (n=5). * P<0.05 vs. Control 
group. Ctrl: control. 
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Fig. 23. Regulation of TRPML1 channel activity by sphingolipids. Summary of the effects 
of various sphingolipids on whole-lysosome currents (n=5). * P<0.05 vs. Ctrl-Vehl group. # 
P<0.05 vs. ML-SA1-Vehl group. Ctrl: control; Vehl: vehicle; SM: sphingomyelin; Cer: 
ceramide; Sph: sphingosine. 
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CHAPTER FIVE 
Albuminuria and podocytopathy induced by podocyte-specific gene deletion of AC α 
subunit 
 
5.1 Characterization of podocyte-specific gene deletion of AC α subunit in 
Asah1fl/fl/PodoCre mice 
To further investigate the physiological relevance of AC inhibition or ceramide metabolism 
in podocytes to glomerular function, we developed a mouse model with podocyte-specific AC 
gene knockout, which is named as Asah1fl/fl/PodoCre mouse colony (Asah1 is AC gene code in 
mice). These mice and their littermates were characterized by several genetic, molecular and 
biochemical approaches. As shown in Fig. 24A, by PCR genotyping, detection of both 
homozygous floxed gene Asah1 and Cre recombinase gene was considered as homozygous mice 
with Cre expression. If neither floxed Asah1 gene nor Cre recombinase gene were detected, the 
mice were wild type (WT/WT). If only floxed Asah1 gene was detected without Cre 
recombinase gene, the mice were Asah1 flox control without podocyte specific deletion 
(Asah1fl/fl/WT). Confocal microscopy showed no colocalization of podocyte marker podocin 
(green fluorescence) and AC α subunit (red fluorescence) in glomeruli of Asah1fl/fl/PodoCre mice, 
compared to WT/WT and Asah1fl/fl/WT mice, which indicates podocyte-specific gene deletion of 
AC α subunit in glomeruli of Asah1fl/fl/PodoCre mice (Fig. 24B). 
 
To further confirm the tissue specific Asah1 gene deletion in podocytes, Asah1fl/fl/PodoCre 
mice were mated with lacZ/EGFP mice to produce Asah1fl/fl/PodoCre+lacZ/EGFP mice. Based on 
previous studies, lacZ/EGFP mice with floxed lacZ express β-galactosidase (lacZ product) 
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throughout embryonic development and adult stages which is driven by CMV promoter. Cre 
excision, however, removes the lacZ gene, which activates expression of the second reporter, 
enhanced green fluorescent protein (EGFP). To detect podocyte-specific expression of β-
galactosidase, the hydrolysis of X-gal to produce a blue color was analyzed.  As shown in Fig. 
25A, the hydrolysis of X-gal in glomeruli was shown by the dark blue staining in the glomeruli 
of lacZ/EGFP mice. However, the dark blue staining in glomeruli of mice with positive 
expression of Asah1fl/fl/PodoCre and lacZ/EGFP genes was much weaker compared with only 
lacZ/EGFP mice because Cre recombinase removed lacZ gene in podocytes. The dark blue 
staining was undetectable in glomeruli of Asah1fl/fl/PodoCre mice due to the lack of lacZ gene. 
 
Using confocal microscopy, we also analyzed the expression of EGFP in the glomeruli of 
Asah1fl/fl/PodoCre mice and their littermates. While the green fluorescence emitted by EGFP was 
undetectable in Asah1fl/fl/PodoCre or lacZ/EGFP mice, colocalization of EGFP (green 
fluorescence) and podocin (red fluorescence) was remarkable in glomeruli of 
Asah1fl/fl/PodoCre+lacZ/EGFP mice (Fig. 25B). This is because expression of EGFP was 
activated when two types of mouse strains were crossbred. Altogether, these results from 
different characterizing protocols confirm podocyte-specific deletion of AC gene in 
Asah1fl/fl/PodoCre mice. 
 
5.2 Ceramide accumulation in glomeruli of Asah1fl/fl/PodoCre mice 
To confirm whether podocyte-specific gene deletion of AC α subunit results in remarkable 
changes of ceramide and sphingosine in podocytes, glomeruli of WT/WT, Asah1fl/fl/WT, and 
Asah1fl/fl/PodoCre mice were isolated for sphingolipid measurement by liquid chromatography 
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tandem mass spectrometry (LC-MS/MS). Fig. 26A shows the representative MS chromatography 
of ceramide in standard and extracts of sphingolipids from glomeruli of mice with different 
genotypes. Seven clear peaks of corresponding to C12, C14, C16, C18, C20, C22, and C24 
ceramides were detected. Total ceramide level and C16 ceramide, the main substrate of AC, 
were analyzed after normalization by glomerulus numbers collected during glomeruli isolation 
from mice. It was found that both total ceramide and C16 ceramide level were much higher in 
glomeruli of Asah1fl/fl/PodoCre mice, compared with WT/WT and Asah1fl/fl/WT mice (Fig. 26B 
and Fig. 26C). On the other hand, there were no significant differences in glomerular 
sphingosine level among mice with different genotypes (Fig. 26D). 
 
5.3 Severe proteinuria and albuminuria induced by podocyte-specific gene deletion of AC 
α subunit 
To determine whether podocyte-specific gene deletion of AC α subunit induce podocyte 
dysfunction and glomerular injury, we measured urinary protein and albumin excretion per 24 
hours of WT/WT, Asah1fl/fl/WT, and Asah1fl/fl/PodoCre mice. As shown in Fig. 27, severe 
proteinuria and albuminuria were found in Asah1fl/fl/PodoCre mice compared with WT/WT and 
Asah1fl/fl/WT mice. To confirm the age at which the podocyte dysfunction and glomerular injury 
were developed in Asah1fl/fl/PodoCre mice, measurements of urinary protein and albumin 
excretion were performed on WT/WT and Asah1fl/fl/PodoCre mice at different ages. No 
significant differences were found in urinary protein and albumin excretion between 4-week-old 
WT/WT and Asah1fl/fl/PodoCre mice. However, when mouse age reached 6 weeks, urinary protein 
and albumin excretions of Asah1fl/fl/PodoCre mice were significantly higher than WT/WT mice. 
After mouse age reaching 8 weeks, severe proteinuria and albuminuria were found in 
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Asah1fl/fl/PodoCre mice compare with WT/WT mice (Fig. 28). These data indicate that podocyte-
specific gene deletion of AC α subunit induces serious podocytopathy, leading to proteinuria and 
albuminuria. 
 
5.4 Podocyte-specific gene deletion of AC α subunit increased permeability to albumin in 
isolated glomeruli 
More evidences were collected by measuring glomerular permeability to albumin of 
WT/WT, Asah1fl/fl/WT, and Asah1fl/fl/PodoCre mice. Glomeruli were isolated in an isotonic HBSS 
solution containing 6% BSA (Fig. 29A). Following a rapid change in the concentration of the 
bath from 6% BSA to 4% BSA, an oncotic gradient of ~9 mmHg was generated. This oncotic 
gradient drove water into the glomerular capillaries, which leads to reduction of the 
concentration and fluorescence intensity of the FITC-dextran in the glomerular capillaries. This 
oncotic pressure-dependent fluid movement within glomeruli can be used for measurement of 
glomerular filtration membrane permeability. As shown in Fig. 29B and 29C, the intensities of 
fluorescence in glomeruli isolated from WT/WT and Asah1fl/fl/WT mice were remarkably 
decreased after a rapid change of the concentration of the bath from 6% BSA to 4% BSA, 
indicating the movement of water into glomerular capillaries of WT/WT and Asah1fl/fl/WT mice 
and normal permeability with barrier for movement of oncotic molecules. On the other hand, 
there were almost no changes in intensities of fluorescence in glomeruli isolated from 
Asah1fl/fl/PodoCre mice after formation of the oncotic gradient, which indicates increased 
glomerular permeability to albumin of Asah1fl/fl/PodoCre mice because oncotic molecules are 
balanced across the glomerular filtration membrane or capillaries to lose driving force for water 
to move into capillaries. These data further confirm that podocyte-specific gene deletion of AC α 
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subunit in mice leads to podocyte dysfunction to produce hyperpermeability damage and 
glomerular injury. 
 
5.5 Undetectable glomerular sclerosis in Asah1fl/fl/PodoCre mice 
By periodic acid Schiff staining, morphological examinations showed no remarkable 
sclerotic changes such as mesangial expansion, collapse of glomerular capillaries, and 
hypercellularity, in glomeruli of Asah1fl/fl/PodoCre mice (Fig. 30A). There was no significant 
increase in glomerular damage index of Asah1fl/fl/PodoCre mice compared with WT/WT mice 
(Fig. 30B). Together, these results indicate that podocyte-specific gene deletion of AC α subunit 
may induce minimal change disease (MCD), a nephrotic syndrome without glomerular 
morphological changes under light microscope. 
 
5.6 Hypoalbuminemia and edema induced by podocyte-specific gene deletion of AC α 
subunit 
Given the clinical signs of minimal change disease are proteinuria, hypoalbuminemia, and 
edema, measurements of serum albumin levels and hematocrits of WT/WT and Asah1fl/fl/PodoCre 
mice were performed to diagnose the podocytopathy induced by podocyte-specific gene deletion 
of AC α subunit. As shown in Fig. 31A, when mouse age reached 8 weeks, Asah1fl/fl/PodoCre 
mice had severe hypoalbuminemia compared with WT/WT mice. Correspondingly, when mice 
became 12-week-old, hematocrits of Asah1fl/fl/PodoCre mice were significantly lower compared 
with WT/WT mice. These results indicate that edema occurs in Asah1fl/fl/PodoCre mice. 
 
5.7 Ultrastructural changes of podocytes in Asah1fl/fl/PodoCre mice 
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Based on previous studies, three hallmarks of MCD include a diffuse loss of foot processes, 
vacuolation, and the appearance of microvilli in podocytes, but there is no loss of podocyte cell 
body from glomerular filtration membrane. Using transmission electron microscopy, we found 
that Asah1fl/fl/PodoCre mice had critical foot process effacement, vacuolation, and formation of 
microvilli in podocytes compared with WT/WT mice (Fig. 32), which showed typical 
ultrastructural pathological changes in podocytes of MCD patients or animals. 
 
5.8 Resistance of podocytopathy in Asah1fl/fl/PodoCre mice to corticosteroid treatment 
Considering that corticosteroids are the most often prescribed medication for MCD 
patients, dexamethasone (DEX), a type of corticosteroid, was i.p. injected to Asah1fl/fl/PodoCre 
mice daily for 4 weeks. As shown in Fig. 33, albuminuria in Asah1fl/fl/PodoCre mice was not 
attenuated by DEX treatment, indicating the steroid resistance of MCD in Asah1fl/fl/PodoCre mice. 
Based on results from in vitro cell studies, podocyte-specific gene deletion of AC α subunit may 
inhibit lysosome function, leading to autophagic deficiency and podocyte dysfunction due to 
induction of dedifferentiation. Therefore, we tested whether daily i.p. injection of rapamycin, an 
activator of entire autophagy process including formation of autophagosomes and their flux, can 
attenuate MCD in Asah1fl/fl/PodoCre mice. It was found that rapamycin treatment for 4 weeks also 
failed to decrease albuminuria in Asah1fl/fl/PodoCre mice (Fig. 34). 
 
5.9 Dystroglycans in Asah1fl/fl/PodoCre mice 
In previous studies, it has been found that reduction of dystroglycans (DGs), a class of 
adhesion proteins, in glomeruli is a hallmark of MCD, which can be reversed if foot processes 
are reconstituted due to treatment or removal of pathogenic factors (143). Some studies have 
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shown that the staining of DGs in glomeruli can differentiate patients with a diagnosis of MCD 
at renal biopsy into groups sensitive or resistant to corticosteroid therapy. It is possible that MCD 
is sensitive to corticosteroid treatment when expressions of both α-DG and β-DG in glomeruli 
are reduced. In contrast, if β-DG is reduced and α-DG is comparable to normal, the MCD 
patients or animals are resistant to corticosteroid treatment (144). For diagnosis, we detected 
expressions of DGs in glomeruli by immunohistochemistry. As shown in Fig. 35, remarkable 
reduction of β-DG in glomeruli was found in Asah1fl/fl/PodoCre mice compared with WT/WT 
mice. However, there were no significant changes in the expression of α-DG in glomeruli 
between WT/WT and Asah1fl/fl/PodoCre mice. These results indicate that podocyte-specific gene 
deletion of AC α subunit may induce steroid-resistant MCD. 
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Fig. 24. Characterization of Asah1fl/fl/PodoCre mice. A. Representative gel documents 
showing detection of floxed Asah1 gene and Cre recombinase gene by PCR Genotyping. B. 
Representative images showing the colocalization of podocin (green fluorescence) and AC α 
subunit (red fluorescence) in glomeruli of different groups of mice (n=6). Cre: Cre 
recombinase; AC-α: AC α subunit. 
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Fig. 25. Confirmation of podocyte-specific expression of Cre recombinase. A. 
Representative images of enzymatic X-gal staining in which dark blue staining in glomeruli 
indicates β-galactosidase expression. B. Representative images showing the colocalization of 
EGFP (green fluorescence) and podocin (red fluorescence) in glomeruli of different groups of 
mice (n=6). OL: overlay. 
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Fig. 26. Ceramide accumulation in glomeruli of Asah1fl/fl/PodoCre mice. A. Representative 
multiple reaction monitoring chromatography of ceramides separated by liquid 
chromatography tandem mass spectrometry. B. Summarized data showing the levels of C16 
ceramide, total ceramide, and sphingosine in isolated glomeruli of different groups of mice 
(n=5-6). * P<0.05 vs. WT/WT group. Cer: ceramide; Sph: sphingosine. 
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Fig. 27. Severe proteinuria and albuminuria in Asah1fl/fl/PodoCre mice. A. Detection of 
severe proteinuria in Asah1fl/fl/PodoCre mice compared with WT/WT and Asah1fl/fl/WT mice 
(n=7-15). B. Detection of severe albuminuria in Asah1fl/fl/PodoCre mice compared with 
WT/WT and Asah1fl/fl/WT mice (n=7-10). * P<0.05 vs. WT/WT group. 
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Fig. 28. Development of proteinuria and albuminuria in Asah1fl/fl/PodoCre mice. A. 
Urinary protein excretion of WT/WT and Asah1fl/fl/PodoCre mice at different ages (n=3-15). B. 
Urinary albumin excretion of WT/WT and Asah1fl/fl/PodoCre mice at different ages (n=3-12). * 
P<0.05 vs. WT/WT group. 
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Fig. 29. Glomerular permeability to albumin increased in Asah1fl/fl/PodoCre mice. A. 
Representative images of isolated glomeruli. B. Representative images showing glomerular 
fluorescence intensities before and after changes of oncotic pressure of different groups of 
mice. C. Summarized data showing responses to different oncotic gradient (n=4-6). * P<0.05 
vs. WT/WT group. 
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Fig. 30. Undetectable glomerular morphological changes in Asah1fl/fl/PodoCre mice under 
light microscope. A. Representative images showing the glomerular morphological changes 
(periodic acid-Schiff staining) of different groups of mice. B. Summarized data of glomerular 
damage indexes of different groups of mice (n=8). 
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Fig. 31. Hypoalbuminemia and edema in Asah1fl/fl/PodoCre mice. A. Serum albumin levels 
of WT/WT and Asah1fl/fl/PodoCre mice at different ages (n=3-7). B. Hematocrits of WT/WT 
and Asah1fl/fl/PodoCre mice at different ages (n=3-9). * P<0.05 vs. WT/WT group. 
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Fig. 32. Ultrastructural changes of podocytes in Asah1fl/fl/PodoCre mice. Representative images 
showing ultrastructural changes in podocytes of Asah1fl/fl/PodoCre mice compared with WT/WT mice 
(n=3). 
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Fig. 33. Resistance of podocytopathy in Asah1fl/fl/PodoCre mice to dexamethasone 
treatment. A. Urinary protein excretion of WT/WT and Asah1fl/fl/PodoCre mice treated with 
vehicle or DEX (n=3-6). B. Urinary albumin excretion of WT/WT and Asah1fl/fl/PodoCre mice 
treated with vehicle or DEX (n=3-6). * P<0.05 vs. WT/WT-Vehl group. Vehl: vehicle; DEX: 
dexamethasone. 
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Fig. 34. Resistance of podocytopathy in Asah1fl/fl/PodoCre mice to rapamycin treatment. 
Urinary protein excretion of WT/WT and Asah1fl/fl/PodoCre mice treated with vehicle or DEX 
(n=3-6). * P<0.05 vs. WT/WT-Vehl group. Vehl: vehicle. 
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Fig. 35. Dystroglycans in Asah1fl/fl/PodoCre mice. Representative immunohistochemical 
staining of α-dystroglycan and β-dystroglycan in glomeruli of WT/WT and Asah1fl/fl/PodoCre 
mice (n=3). 
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CHAPTER SIX 
DISCUSSION 
 
6.1 Enhanced podocyte dedifferentiation associated with autophagic deficiency due to 
lysosome dysfunction 
The major goals of our first series of studies were to determine whether lysosome 
dysfunction-induced podocyte dedifferentiation is attributed to the accumulation of 
autophagosome and p62, which are degraded by autophagic process and to explore the 
mechanisms by which accumulation of p62 exerts its action as a signaling hub to activate or 
enhance dedifferentiation in podocytes. It was found that lysosome function inhibition with a low 
dose of lysosomal V-ATPase inhibitor, Baf A1 (5 nM) or by silencing V-ATPase gene 
remarkably enhanced podocyte dedifferentiation, which was accompanied by autophagosome 
accumulation due to the deficient autophagic flux. This enhancement of dedifferentiation in 
podocytes was significantly attenuated by inhibition of the autophagosome formation with Sp-1, 
suggesting that autophagosome accumulation in podocytes contributes to enhanced 
dedifferentiation induced by lysosome dysfunction. We further explored the signaling 
mechanisms activating or enhancing podocyte dedifferentiation associated with lysosome 
dysfunction. Given that p62 was found significantly increased during lysosome dysfunction and 
resulting deficiency of autophagic flux, several signaling pathways regulated via p62 were tested 
including Nrf2-mediated redox signaling, NF-κB-dependent transcriptional regulation, and 
CDK1-mediated phosphorylation of p62 as an intracellular controller of cell mitosis exit. Our 
results indicate that reduction of CDK1-mediated p62 phosphorylation and consequent speeding 
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exit of cell mitosis are a critical molecular mechanism mediating podocyte dedifferentiation 
during lysosome dysfunction. 
 
It has been reported that podocytes in glomeruli of mammalian animals are highly 
differentiated and therefore the maintenance of functional and structural integrity of these cells 
during their long time surviving are much dependent upon the autophagic process, which 
includes the formation and degradation of autophagosomes (89). This led us to hypothesize that 
lysosome dysfunction and consequent derangement of autophagic flux may be an important 
mechanism activating or enhancing dedifferentiation in podocytes, leading to podocyte injury 
and glomerular sclerosis. This hypothesis was tested in the present study by inhibition of 
lysosome function using V-ATPase inhibitor, Baf A1 (Baf A1) and specific V-ATPase siRNA. 
We indeed demonstrated that inhibition of lysosome function by Baf A1 and V-ATPase siRNA 
significantly enhanced dedifferentiation in podocytes, which was comparable to that produced by 
a well-established dedifferentiation inducer, TGF-β (15, 145) or by inhibition or knocking down 
of CD38, an enzyme for production of an endogenous regulator of lysosome function, NAADP 
(88, 89). To our knowledge, these results represent the first experimental evidence that inhibition 
of lysosomal V-ATPase activity or its gene silencing activated or enhanced podocyte 
dedifferentiation. In previous studies, some molecular mechanisms have been proposed to 
activate dedifferentiation in other cell or tissue types, which are similar to those regulating 
oncogenic properties in neoplastic cells such as proliferation, resistance to apoptosis and 
angiogenesis through transcription factors (26). However, these mechanisms are found mainly 
related to ubiquitination, namely, the covalent link of the small 76-amino acid protein ubiquitin 
to target proteins, which serves as a signal for many proteins to be degraded by the proteasomes 
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(26). Although lysosomal degradation of some signaling proteins may be one of mechanisms 
responsible for dedifferentiation, little is known so far how lysosome dysfunction induces 
dedifferentiation in many cell types including podocytes. In this regard, some previous studies 
demonstrated that Raf and TGF-β may work together to promote lysosomal degradation of E-
cadherin instead of its recycling in tumor cells, resulting in dedifferentiation and tumor 
progression (146). Despite these observations of lysosomal degradation of signaling proteins in 
dedifferentiation, it remains unknown how lysosomal degradation of signaling proteins activates 
dedifferentiation. In particular, it is interesting to know whether the reversal of differentiation 
induced by autophagy, a process fine controlled by lysosome function, contributes to 
dedifferentiation in podocytes. If so, we need to test what is the triggering mechanism. 
 
We first examined whether enhanced dedifferentiation during lysosome dysfunction is 
associated with deficient autophagy, in particular, the autophagic flux, given the important role 
of lysosomes in this process. It was demonstrated that autophagosome and p62, a scaffold protein 
also in autophagic process, were largely accumulated in podocytes by Baf A1 or silencing of v-
ATPase gene, suggesting that lysosome function inhibition leads to abnormal autophagic flux 
and thereby reduces autophagic degradation of ubiquitinated cargoes and functional substrates 
involved in the autophagic process such as p62 (133, 147-149). We also demonstrated that 
inhibition of autophagosome formation by Sp-1 significantly attenuated the enhancement of 
dedifferentiation induced by lysosome dysfunction induced by Baf A1 and V-ATPase siRNA. To 
our knowledge, these results provide the first evidence that autophagosome accumulation may 
serve as a critical mechanism activating or enhancing dedifferentiation in podocytes. In some 
previous studies, autophagy was shown to be critical for the invasion of tumor cells, which is 
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associated with the induction of dedifferentiation and activation of TGF-β/Smad3-dependent 
signaling pathway (150). In addition, the autophagy process and the autophagy-mediated 
lysosomal degradation of SNAI/Snail and TWIST, two master inducers of the dedifferentiation 
process have been reported to mediate the effects of death effector domain-containing DNA-
binding protein (DEDD) to alter tumor growth and metastasis, suggesting that autophagy is 
involved in dedifferentiation and subsequent growth or metastasis of tumors (151, 152). 
 
After confirmation of deficient autophagic flux as an important process, we went on to 
address how Baf A1-induced accumulation of autophagosome initiated dedifferentiation in 
podocytes. It has been reported that p62 as a signaling hub regulates cell proliferation and many 
other activities (153, 154) and that in tumor cells, p62 is required for cell transformation (153, 
155, 156). Interestingly, the genetic inactivation of key autophagy molecules, such as Atg7, 
results in p62 accumulation and hepatotoxicity, which leads to the generation of liver tumors 
(153, 155), suggesting the important association of autophagic process of p62 with tumorigenesis 
or cell transdifferentiation. We tested the role of 3 pathways regulated p62 in podocyte 
dedifferentiation, which include NF-κB, Nrf2 and cyclin-dependent kinases (CDKs). Using 
selective inhibitor or siRNAs, we found that inhibition of NF-κB and Nrf2 signaling pathways 
had no effect on Baf A1-induced dedifferentiation in podocytes, suggesting that both pathways 
are not involved in this podocytes transdifferentiation induced by lysosome dysfunction. 
However, inhibition of CDK1 activity or silencing its gene produced podocyte dedifferentiation 
without effect on the level of p62. In the presence of CDK1 inhibitor or siRNA, Baf-induced 
podocyte dedifferentiation was markedly attenuated by 60%, which was accompanied by 
significantly reduced phosphorylation of p62 in these podocytes. These results suggest that 
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CDK1 phosphorylation exerts an important regulatory role on podocyte dedifferentiation and 
that reduced CDK1 phosphorylation may result in enhancement of this dedifferentiation. To our 
knowledge, there have been no reports on the role of CDK1-mediated p62 phosphorylation in the 
regulation of podocytes differentiation or transdifferentiation. Our results provide direct evidence 
that this CDK1-mediated mechanism critically contributes to dedifferentiation activation. In 
studies using other cell types, CDKs were demonstrated to regulate the progression of 
mammalian cells through the various phases of the cell cycle (157). Among these CDKs, CDK1 
controls transit through the late S/G2 phase and early mitosis phase of the cell cycle (158, 159), 
which may be associated with p62 phosphorylation at residues T269 and S272 (160, 161). In 
cancer cells, expression of a nonphosphorylatable p62 mutant displayed higher tumorigenic 
properties than the same cells expressing wild-type p62 (161). Moreover, p62 phosphorylation 
has been shown to play an important role in the stabilization of cyclin B1, which interacts with 
CDK1 to specifically regulate the entry into mitosis (161). Our findings together with these 
previous results provide strong evidence that reduced phosphorylation of p62 due to inhibition of 
CDK1 during lysosome dysfunction leads to a faster exit from cell mitosis and thereby enhances 
dedifferentiation in podocytes, which is resulted from accumulation of p62 induced by deranged 
autophagic flux. 
 
In summary, the first series of studies revealed a new triggering mechanism of podocyte 
dedifferentiation during lysosome dysfunction, which is characterized by deranged autophagic 
flux, p62 accumulation and associated reduction of p62 phosphorylation. This dysregulation of 
p62 and its CDK1-dependent phosphorylation may represent a novel early event leading to 
podocyte dysfunction, which may initiate podocytes injury and ultimately result in 
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glomerulosclerosis during lysosome dysfunction. These results may direct toward the 
development of new therapeutic strategies targeting phosphorylation of p62 for prevention or 
treatment of glomerular sclerosis associated with lysosome dysfunction and deficient autophagy 
under different pathological conditions such as hypercholesterolemia, hyperhomocysteinemia or 
diabetes mellitus. 
 
6.2 Deficient lysosome trafficking in response to altered ceramide metabolism and 
associated inhibition of TRPML1 channel activity 
The major goals of our second series of studies were to determine whether dysfunction of 
AC leads to deficient lysosome trafficking in podocytes and to explore the mechanisms by which 
AC controls lysosome trafficking with a focus on the regulation of TRPML1 channel activity by 
AC. It was found that inhibition of AC with a selective AC inhibitor, Carmofur, remarkably 
inhibited lysosome trafficking and fusion to autophagosomes or MVBs in podocytes. This 
inhibition of lysosome trafficking in podocytes was significantly attenuated by activation of AC 
with genistein or addition of sphingosine, suggesting that production of sphingosine by AC 
contributes to lysosome trafficking in podocytes. We further explored the molecular mechanisms 
mediating lysosome trafficking dependent on AC activity. Given that Ca2+ release plays an 
essential role in lysosome trafficking through dynein-microtubule system and TRPML1 has been 
confirmed to be a lysosomal Ca2+ channel, we tested whether AC contributes to lysosome 
trafficking through activation of TRPML1 channel. Our results indicate that reduction of AC 
activity and consequent inhibition of TRPML1 channel are a critical molecular mechanism 
mediating lysosome dysfunction or blunted lysosome trafficking in podocytes. 
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It has been reported that lysosomes have trafficking function and lysosome trafficking is a 
main regulatory mechanism of autophagic flux, which may depend upon the Ca2+ release from 
lysosomes (96-102). It is well known that Ca2+ enters lysosomal compartment by H+/Ca2+ 
exchange under resting condition and is released through transient receptor potential-mucolipin-1 
(TRPML1) channels in response to endogenously produced NAADP (103, 107, 108, 117, 118) 
or other factors like PIPs (PI(3,5)P2) and irons (109, 111, 119). More recently, lysosomal 
TRPML1 channel activity regulated by sphingolipids has been shown to be a key mechanism 
determining lysosome trafficking (112, 121). This led us to hypothesize that dysfunction of AC, 
a lysosomal enzyme for ceramide metabolism, may inhibit TRPML1 channel activity and 
consequent Ca2+ release from lysosomes, leading to lysosome dysfunction and autophagic 
deficiency in podocytes. This hypothesis was tested in the present study by inhibition of AC 
function using a selective AC inhibitor, carmofur. We demonstrated that inhibition of AC 
function by carmofur significantly attenuated lysosome trafficking and fusion to autophagosomes 
or MVBs in podocytes, which was comparable to that produced by a well-established V-ATPase 
inhibitor, Baf A1 or by inhibition or knocking down of CD38, an enzyme for production of an 
endogenous agonist of TRPML1 channel, NAADP (89). To our knowledge, these results 
represent the first experimental evidence that inhibition of lysosomal AC activity blocked 
lysosome trafficking in podocyte.  
 
In previous studies, some molecular mechanisms have been proposed to be involved in 
lysosome trafficking, such as CD38-NAADP-TRPML1 system (89, 141, 142), dynein-
microtubule system (162), vesicle-associated membrane protein 2 (VAMP-2) (163), and 
dysferlin C2A domain (164). Recent studies in our laboratory have found that activation of ASM 
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contributes to lysosome trafficking in coronary arterial endothelial cells (CAECs) (134, 135) and 
coronary arterial smooth muscle cells (CASMCs) (136). However, the mechanism mediating the 
role of ASM in lysosome trafficking and autophagic flux remains unknown. In this regard, some 
previous studies demonstrated that sphingolipids control lysosome trafficking via regulation of 
TRPML1 channel activity in cells transfected with TRPML1 channel plasmids (112, 121). It was 
found that sphingomyelin inhibited TRPML1 channel activity while sphingosine enhanced 
TRPML1 channel activation induced by its stimulator. On the other hand, ceramide had no 
effects on TRPML1 channel activity. In the present study, it is interesting to know whether the 
metabolism of ceramide to sphingosine, a process fine controlled by lysosomal AC, contributes 
to TRPML1 channel activation and consequent lysosome trafficking in podocytes. 
 
To test our hypothesis, we examined whether inhibition of AC activity is associated with 
dysfunction of TRPML1 channel in podocytes by GCaMP3 Ca2+ imaging. It was demonstrated 
that the selective AC inhibitor, Carmofur, totally blocked ML-SA1-induced Ca2+ release through 
TRPML1 channel, suggesting that normal function of AC is essential for TRPML1 channel 
activity. We also demonstrated that addition of sphingosine to the external solution, the product 
of ceramide metabolism by AC, significantly increased Ca2+ release through TRPML1 channel 
compared with treatment with sphingosine-1-phosphate (S1P). Since sphingomyelin and C16 
ceramide, the substrate of AC, are impermeable to plasma membrane, we used whole-lysosome 
patch clamp recording to further confirm the roles of different sphingolipids in TRPML1 channel 
activity. We found that ML-SA1-induced Ca2+ release through TRPML1 channel from lysosome 
was blocked by sphingomyelin. However, sphingosine as the product of ceramide metabolism by 
AC remarkably enhanced ML-SA1-induced TRPML1 channel activation. It was found that 
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ceramide had no effects on ML-SA1-induced Ca2+ release through TRPML1 channel. To our 
knowledge, these results provide the first evidence that ceramide metabolism by AC may serve 
as a critical mechanism mediating TRPML1 channel activation in podocytes. It has been reported 
that lysosomal accumulation of SM by ASM deficiency inhibits the activity of TRPML1 and 
thereby blocks the lysosomal Ca2+-dependent membrane trafficking (112). A target protein 
regulated by lysosomal Ca2+ is dynein, a multi-subunit microtubule motor protein complex, 
which is responsible for nearly all minus-end microtubule-based transport of vesicles within 
eukaryotic cells and is recently implicated in lysosome and autophagosome (AP) trafficking to 
meet and form autophagolysosomes (ALPs) (165, 166). Inhibition or loss of dynein function 
abolished lysosome fusion with APs and increases the number of APs in glioma, or neuronal 
cells, and in CASMCs (166, 167). These previous studies have suggested that ASM-regulated 
lysosomal trafficking function may be associated with the level of lysosomal SM via regulating 
TRPML1/lysosomal Ca2+/dynein signaling axis. Recent studies in our lab have also 
demonstrated that ASM is critical for the fusion of lysosome and autophagosome. The control of 
lysosome trafficking and fusion by ASM is essential to a normal autophagic flux (136). In 
addition, ASM was found to be essential for lysosomal trafficking, membrane fusion and 
formation of membrane raft (MR) redox signaling platforms (134, 135). However, none of these 
studies have elucidated the mechanisms mediating the role of ASM in lysosome trafficking. In 
the present study, we have demonstrated different effects of various sphingolipids on TRPML1 
channel activity, which may define the molecular mechanism for control of lysosome trafficking 
by both ASM and AC. 
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In summary, the second series of studies revealed a new molecular mechanism mediating 
lysosome trafficking in podocytes, which is characterized by signaling via AC-dependent 
ceramide metabolism and TRPML1 channel activation. The hydrolysis of ceramide by AC may 
plays an essential role in governing TRPML1 channel activity and thereby contributes to 
lysosome trafficking and fusion to autophagosome in podocytes. These results may direct toward 
the development of new therapeutic strategies targeting AC for prevention or treatment of 
podocyte dedifferentiation or dysfunction associated with lysosome dysfunction and deficient 
autophagy under different pathological conditions. 
 
6.3 Podocytopathy and albuminuria induced by podocyte-specific gene knockout of AC α 
subunit 
The major goal of our third series of studies was to determine whether podocyte-specific 
gene knockout of AC α subunit induces podocyte dedifferentiation or dysfunction, leading to 
glomerular injury and diseases. For this purpose, Asah1fl/fl/PodoCre mice were generated. We first 
confirmed remarkable accumulation of ceramide in glomeruli of Asah1fl/fl/PodoCre mice. Our data 
showed that podocyte-specific gene knockout of AC α subunit induces severe proteinuria and 
albuminuria. Glomerular permeability to albumin was remarkably increased in Asah1fl/fl/PodoCre 
mice. However, glomerular morphological changes were undetectable under light microscope, 
which indicate that podocyte-specific gene knockout of AC α subunit and ceramide 
accumulation only in podocyte may induce minimal change disease (MCD). More features of 
MCD, such as hypoalbuminemia and edema, were also confirmed in Asah1fl/fl/PodoCre mice. By 
transmission electron microscopy, ultrastructural changes of podocyte were found in 
Asah1fl/fl/PodoCre mice, which included diffuse foot process effacement, vacuolation, and 
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microvillus formation. In treatment experiments of MCD, we confirmed the resistance to 
corticosteroid of MCD in Asah1fl/fl/PodoCre mice. Our results indicate that AC activity is essential 
for maintaining the integrity and function of podocytes and lack of AC activity is an important 
inducer of podocyte dysfunction and glomerular injury, which may be a new pathogenic 
mechanism of proteinuria or MCD. 
 
Acid ceramidase (AC) was identified by Gatt in 1963 (168), but it was purified in 1995, 
which was first isolated from human urine (169). AC is the lipid hydrolase responsible for the 
degradation of ceramide into sphingosine and free fatty acids within lysosomes. Farber disease is 
a lysosomal storage disease caused by the inherited deficiency of AC activity (170). In most 
cases, the disease is diagnosed early in life with typical symptoms including deformed joints, 
subcutaneous nodules, and progressive hoarseness (171). In 2002, the global AC knockout 
mouse model was created by Li et al. (172), but it could not be used for physiological studies 
because some insertional mutagenesis of the mouse AC gene leads to early embryonic lethality 
in homozygotes. In addition, AC not only hydrolyzes ceramide into sphingosine, but also can 
synthesize ceramide from sphingosine and free fatty acids in vitro and in situ under certain 
conditions (173). This "reverse" enzymatic activity occurs at a distinct pH from the hydrolysis 
("forward") reaction (6.0 vs. 4.5, respectively), suggesting that the enzyme may have diverse 
functions within cells dependent on its subcellular location and the local pH. Since AC α subunit 
is primarily responsible for posttranslational positioning of AC to lysosomes, gene deletion of 
AC α subunit may totally blocked the normal function of lysosomal AC. In the present study, 
Asah1fl/fl/PodoCre mouse colony was the first mouse model, in which we could study the role of 
AC activity in the integrity and function of podocytes. Given the in vitro evidences in the present 
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study, we tested whether podocyte-specific deficiency of AC activity induces podocyte 
dysfunction, leading to glomerular injury and proteinuria. 
 
After characterization of podocyte-specific gene deletion of AC α subunit, we first 
examined whether podocyte-specific deficiency of AC activity results in ceramide accumulation 
in glomeruli of Asah1fl/fl/PodoCre mice. It was found that podocyte-specific deficiency of AC 
activity induced significant increase in ceramide in glomeruli of Asah1fl/fl/PodoCre mice. On the 
other hand, sphingosine as the product of ceramide metabolism by AC had no changes in 
Asah1fl/fl/PodoCre mice compared with WT/WT and Asah1fl/fl/WT mice. We further tested 
whether podocyte-specific gene deletion of AC α subunit leads to podocyte injury and associated 
proteinuria. It was demonstrated that Asah1fl/fl/PodoCre mice had serious proteinuria and 
albuminuria compared with WT/WT and Asah1fl/fl/WT mice, suggesting that gene deletion of 
AC α subunit induced severe podocyte injury. In vitro experiment using isolated glomeruli 
demonstrated that glomerular permeability to albumin were remarkably increased in 
Asah1fl/fl/PodoCre mice compared with WT/WT and Asah1fl/fl/WT mice. To our knowledge, these 
data for the first time showed that lysosomal AC activity is essential for maintenance of the 
functional integrity of podocytes and glomeruli. In this regard, previous studies have reported 
that ceramide is implicated in the regulation of renal function, which is mainly considered as a 
potent regulator of cell proliferation, activation, and apoptosis (174). However, this lipid 
mediator has shown to mediate the detrimental or pathogenic actions of many different injury 
factors in different cells and tissues (174-176). For example, we have demonstrated by 
pharmacological and genetic interventions that ceramide contributes to the development of 
chronic glomerular injury associated with hyperhomocysteinemia (hHcys) and obesity (177, 
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178). Recent studies in our lab have reported that overproduction of ceramide by ASM activation 
contributes to podocyte injury and glomerular sclerosis during hHcys and obesity (93-95). The 
NADPH-dependent superoxide production and consequent NLRP3 inflammasome activation 
may be the molecular mechanism mediating podocyte injury and glomerular sclerosis induced by 
ASM activation and ceramide accumulation. These pathological changes were remarkably 
attenuated in global ASM gene knockout mice compared with WT/WT mice. The present study 
further increase our knowledge that AC gene defect or deficiency of AC activity even only in 
podocyte is involved in the development of podocyte injury. 
 
With interesting results obtained in our functional studies, we went on to examine whether 
glomerular sclerosis was developed in Asah1fl/fl/PodoCre mice. Surprisingly, glomerular 
morphological changes were undetectable in Asah1fl/fl/PodoCre mice under light microscope. 
These results indicate that minimal change disease (MCD) may occur in Asah1fl/fl/PodoCre mice 
because MCD is defined as a type of nephrotic syndrome characterized by albuminuria, but 
histopathologically lacking global or even focal segmental glomerular sclerotic changes under 
light microscope. Another feature of MCD is foot process (FP) effacement or flatting process of 
podocyte as seen by electron microscopy (179). To further confirm the development of MCD in 
Asah1fl/fl/PodoCre mice, we measured serum albumin levels and hematocrits in WT/WT and 
Asah1fl/fl/PodoCre mice. As another classical MCD feature, obvious hypoalbuminemia and edema 
were observed in Asah1fl/fl/PodoCre mice, but not in WT/WT mice. By transmission electron 
microscopy, diffuse foot process effacement, vacuolation, and microvillus formation were 
observed in Asah1fl/fl/PodoCre mice, but not in WT/WT mice. Together, these results firmly 
confirm that podocyte-specific deletion leads to MCD in mice. To our knowledge, so far this is 
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the only study that links deficient AC activity and associated ceramide accumulation to the 
development of MCD, which may be novel pathogenic mechanisms for MCD and a novel 
therapeutic therapy targeting AC deficiency may be a future research direction. 
 
With respect to the pathogenesis and pathophysiology, podocyte injury in MCD may be 
idiopathic, genetic, or reactive (144). The major clinical distinction among subgroups of this 
category is the responsiveness to glucocorticoid therapy. It has been reported that idiopathic and 
reactive forms of MCD may be generally steroid sensitive. Steroid-resistant forms have a similar 
morphology but worse outcome and likely have distinct etiologies. In this regard, idiopathic 
MCD is typically steroid sensitive, particularly in children. Medications that are effective in 
treating reactive MCD may affect the cellular immune system. Cell-mediated immunity has been 
invoked as an etiologic factor in the development of reactive MCD (180). Three genetic forms of 
genetic MCD have been identified. Steroid-resistant MCD that presents in infancy or childhood 
with autosomal recessive inheritance may be caused by mutations in NPHS2, encoding podocin. 
Autosomal dominant nephrotic syndrome, presenting as focal segmental glomerular sclerosis 
(FSGS) or less commonly as MCD, has been linked to a nearby locus on chromosome 19q, for 
which the gene remains unidentified (181, 182). Recently, MCD was reported in a patient with 
limb girdle muscular dystrophy type 2B, which is caused by mutations in dysferlin (DYSF) 
(183). To confirm which subtype of MCD was developed in Asah1fl/fl/PodoCre mice, 
dexamethasone (DEX) as a medical corticosteroid was used to treat these mice and their 
littermates. It was found that DEX had no protective effects on any functional and structural 
changes in podocytes and glomerular in Asah1fl/fl/PodoCre mice after treatment for 4 weeks. It 
seems that MCD in Asah1fl/fl/PodoCre mice may be resistant to steroid treatment, which is 
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consistent with genetic MCD. It is possible that AC deficiency interfered with podocin synthesis 
leading to MCD as shown by mutations of NPHS2. In addition, it has been reported that the 
staining for dystroglycan may segregate patients with a diagnosis of MCD at renal biopsy into 
one group of patients with a high likelihood of favorable response to corticosteroid therapy and 
another group of patients with poor response to the steroid therapy (143, 144). To further 
confirm whether steroid-resistant MCD was developed in Asah1fl/fl/PodoCre mice, we detected the 
expression of dystroglycans in glomeruli by immunohistochemistry. It was found that β-
dystroglycan was remarkably decreased in glomeruli of Asah1fl/fl/PodoCre mice compared with 
WT/WT mice. On the other hand, there were no significant changes in glomerular α-
dystroglycan between WT/WT mice and Asah1fl/fl/PodoCre mice. Such results with decreased β-
dystroglycans and unchanged α-dystroglycan indeed indicate the occurrence of corticosteroid 
resistant MCD in Asah1fl/fl/PodoCre mice.  
 
In previous studies, ceramide has been shown to block insulin action by inhibiting insulin 
signal transduction in cultured adipocytes or myotubes (184-187). Moreover, intracellular levels 
of ceramide are elevated in rodent or human skeletal muscles made insulin resistant by either 
obesity (188, 189) or acute lipid infusion (190). By contrast, exercise training, which improves 
insulin sensitivity, markedly decreases muscle ceramide levels in both rats and humans (191-
193). Recently, it has been reported that saturated FFA-induced ceramide accumulation 
contributes to the development of saturated fat-induced muscle insulin resistance (194). 
Overexpression of AC can protect cells from the inhibitory effects of palmitate and other long-
chain saturated FFAs on insulin signaling. It is possible that podocyte-specific gene deletion of 
AC α subunit may induce insulin resistance in podocytes, leading to podocyte injury even at 
 100 
normal blood glucose level, which is similar to pathological changes at early stage of Type 2 
diabetes. Such podocyte injury due to enhanced insulin resistance has been reported in studies by 
podocyte-specific deletion of insulin receptor. This possibility will be explored in our future 
studies. 
 
In summary, the third series of studies revealed that podocyte-specific gene deletion of AC 
α subunit may be a potential triggering mechanism of corticosteroid-resistant MCD, which is 
characterized by albuminuria, hypoalbuminemia, edema, undetectable glomerular morphological 
changes under light microscope, and podocyte effacement or projection flatting. These results 
reveal a novel pathogenic mechanism for MCD and may direct toward the development of new 
therapeutic strategies for treatment of MCD by targeting dysfunction of AC deficiency and 
associated ceramide. 
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